PPARalpha	O
activators	O
inhibit	O
cytokine-induced	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
expression	O
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

BACKGROUND	O
:	O
Adhesion	O
molecule	O
expression	O
on	O
the	O
endothelial	O
cell	O
(	O
EC	O
)	O
surface	O
is	O
critical	O
for	O
leukocyte	O
recruitment	O
to	O
atherosclerotic	O
lesions	O
.	O

Better	O
understanding	O
of	O
transcriptional	O
regulation	O
of	O
adhesion	B-protein
molecules	I-protein
in	O
ECs	B-cell_type
may	O
provide	O
important	O
insight	O
into	O
plaque	O
formation	O
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptor-alpha	I-protein
(	O
PPARalpha	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
family	I-protein
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
certain	O
fatty	O
acids	O
and	O
fibric	O
acid	O
derivatives	O
.	O

The	O
present	O
study	O
investigated	O
PPARalpha	B-protein
expression	O
in	O
human	B-cell_type
ECs	I-cell_type
and	O
their	O
regulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Immunohistochemistry	O
revealed	O
that	O
human	B-cell_type
carotid	I-cell_type
artery	I-cell_type
ECs	I-cell_type
express	O
PPARalpha	B-protein
.	O

Pretreatment	O
of	O
cultured	B-cell_type
human	I-cell_type
ECs	I-cell_type
with	O
the	O
PPARalpha	B-protein
activators	O
fenofibrate	O
or	O
WY14643	O
inhibited	O
TNF-alpha-induced	B-protein
VCAM-1	I-protein
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
,	O
an	O
effect	O
not	O
seen	O
with	O
PPARgamma	B-protein
activators	O
.	O

Both	O
PPARalpha	B-protein
activators	O
decreased	O
cytokine-induced	O
VCAM-1	B-protein
mRNA	O
expression	O
without	O
altering	O
its	O
mRNA	O
half-life	O
.	O

Transient	O
transfection	O
of	O
deletional	O
VCAM-1	B-DNA
promoter	I-DNA
constructs	I-DNA
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
fenofibrate	O
inhibits	O
VCAM-1	B-protein
transcription	O
in	O
part	O
by	O
inhibiting	O
NF-kappaB	B-protein
.	O

Finally	O
,	O
PPARalpha	B-protein
activators	O
significantly	O
reduced	O
adhesion	O
of	O
U937	B-cell_line
cells	I-cell_line
to	O
cultured	B-cell_type
human	I-cell_type
ECs	I-cell_type
.	O

CONCLUSIONS	O
:	O
Human	B-cell_type
ECs	I-cell_type
express	O
PPARalpha	B-protein
,	O
a	O
potentially	O
important	O
regulator	O
of	O
atherogenesis	O
through	O
its	O
transcriptional	O
control	O
of	O
VCAM-1	B-protein
gene	O
expression	O
.	O

Such	O
findings	O
also	O
have	O
implications	O
regarding	O
the	O
clinical	O
use	O
of	O
lipid-lowering	O
agents	O
,	O
like	O
fibric	O
acids	O
,	O
which	O
can	O
activate	O
PPARalpha	B-protein
.	O

iduosnuepy	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuepy	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Yd-HIN	NULL
wrt	NULL
!	NULL

o	NULL
MWg	NULL
€	NULL
7	NULL
»	NULL
4	NULL
&	NULL
NIH	NULL
Public	NULL
Access	NULL
Author	NULL
Manuscript	NULL
Published	NULL
in	NULL
final	NULL
edited	NULL
form	NULL
as	NULL
:	NULL
Circulation	NULL
.	NULL

1999	NULL
June	NULL
22	NULL
;	NULL
99	NULL
(	NULL
24	NULL
)	NULL
:	NULL
3125-3131	NULL
.	NULL

PPARa	NULL
Activators	NULL
Inhibit	NULL
Cytokine-Induced	NULL
Vascular	NULL
Cell	NULL
Adhesion	NULL
Molecule-1	NULL
Expression	NULL
in	NULL
Human	NULL
Endothelial	NULL
Cells	NULL
Nikolaus	NULL
Marx	NULL
,	NULL
MD	NULL
,	NULL
Galina	NULL
K.	NULL
Sukhova	NULL
,	NULL
PhD	NULL
,	NULL
Tucker	NULL
Collins	NULL
,	NULL
MD	NULL
,	NULL
PhD	NULL
,	NULL
Peter	NULL
Libby	NULL
,	NULL
MD	NULL
,	NULL
and	NULL
Jorge	NULL
Plutzky	NULL
,	NULL
MD	NULL
Vascular	NULL
Medicine	NULL
and	NULL
Atherosclerosis	NULL
Unit	NULL
,	NULL
Cardiovascular	NULL
Division	NULL
(	NULL
N.M.	NULL
,	NULL
G.K.S	NULL
.	NULL

,	NULL
P.L	NULL
.	NULL

,	NULL
J.P.	NULL
)	NULL
and	NULL
the	NULL
Vascular	NULL
Research	NULL
Division	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
(	NULL
T.C	NULL
.	NULL
)	NULL

,	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
Abstract	NULL
Background-Adhesion	NULL
molecule	NULL
expression	NULL
on	NULL
the	NULL
endothelial	NULL
cell	NULL
(	NULL
EC	NULL
)	NULL
surface	NULL
is	NULL
critical	NULL
for	NULL
leukocyte	NULL
recruitment	NULL
to	NULL
atherosclerotic	NULL
lesions	NULL
.	NULL

Better	NULL
understanding	NULL
of	NULL
transcriptional	NULL
regulation	NULL
of	NULL
adhesion	NULL
molecules	NULL
in	NULL
ECs	NULL
may	NULL
provide	NULL
important	NULL
insight	NULL
into	NULL
plaque	NULL
formation	NULL
.	NULL

Peroxisome	NULL
proliferator-activated	NULL
receptor-a	NULL
(	NULL
PPARa	NULL
)	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
nuclear	NULL
receptor	NULL
family	NULL
,	NULL
regulates	NULL
gene	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
certain	NULL
fatty	NULL
acids	NULL
and	NULL
fibric	NULL
acid	NULL
derivatives	NULL
.	NULL

The	NULL
present	NULL
study	NULL
investigated	NULL
PPARa	NULL
expression	NULL
in	NULL
human	NULL
ECs	NULL
and	NULL
their	NULL
regulation	NULL
of	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
(	NULL
VCAM-1	NULL
)	NULL
.	NULL

Methods	NULL
and	NULL
Results-Immunohistochemistry	NULL
revealed	NULL
that	NULL
human	NULL
carotid	NULL
artery	NULL
ECs	NULL
express	NULL
PPARa	NULL
,	NULL
.	NULL

Pretreatment	NULL
of	NULL
cultured	NULL
human	NULL
ECs	NULL
with	NULL
the	NULL
PPARa	NULL
activators	NULL
fenofibrate	NULL
or	NULL
WY14643	NULL
inhibited	NULL
TNF-a-induced	NULL
VCAM-1	NULL
in	NULL
a	NULL
time-and	NULL
concentration-dependent	NULL
manner	NULL
,	NULL
an	NULL
effect	NULL
not	NULL
seen	NULL
with	NULL
PPARy	NULL
activators	NULL
.	NULL

Both	NULL
PPARa	NULL
activators	NULL
decreased	NULL
cytokine-induced	NULL
VCAM-1	NULL
mRNA	NULL
expression	NULL
without	NULL
altering	NULL
its	NULL
mRNA	NULL
half-life	NULL
.	NULL

Transient	NULL
transfection	NULL
of	NULL
deletional	NULL
VCAM-1	NULL
promoter	NULL
constructs	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
suggest	NULL
that	NULL
fenofibrate	NULL
inhibits	NULL
VCAM-1	NULL
transcription	NULL
in	NULL
part	NULL
by	NULL
inhibiting	NULL
NF-xB	NULL
.	NULL

Finally	NULL
,	NULL
PPARa	NULL
activators	NULL
significantly	NULL
reduced	NULL
adhesion	NULL
of	NULL
U937	NULL
cells	NULL
to	NULL
cultured	NULL
human	NULL
ECs	NULL
.	NULL

Conclusions-Human	NULL
ECs	NULL
express	NULL
PPARa	NULL
,	NULL
a	NULL
potentially	NULL
important	NULL
regulator	NULL
of	NULL
atherogenesis	NULL
through	NULL
its	NULL
transcriptional	NULL
control	NULL
of	NULL
VCAM-1	NULL
gene	NULL
expression	NULL
.	NULL

Such	NULL
findings	NULL
also	NULL
have	NULL
implications	NULL
regarding	NULL
the	NULL
clinical	NULL
use	NULL
of	NULL
lipid-lowering	NULL
agents	NULL
,	NULL
like	NULL
fibric	NULL
acids	NULL
,	NULL
which	NULL
can	NULL
activate	NULL
PPARa	NULL
.	NULL

Keywords	NULL
atherosclerosis	NULL
;	NULL
endothelium	NULL
;	NULL
leukocytes	NULL
©1999	NULL
American	NULL
Heart	NULL
Association	NULL
,	NULL
Inc	NULL
.	NULL

Correspondence	NULL
to	NULL
Jorge	NULL
Plutzky	NULL
,	NULL
MD	NULL
,	NULL
Vascular	NULL
Medicine	NULL
and	NULL
Atherosclerosis	NULL
Unit	NULL
,	NULL
Cardiovascular	NULL
Division	NULL
,	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
221	NULL
Longwood	NULL
Ave	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115.	NULL
jplutzky	NULL
@	NULL
rics.bwh.harvard.edu	NULL
.	NULL

Drs	NULL
Libby	NULL
and	NULL
Plutzky	NULL
are	NULL
speakers/consultants	NULL
for	NULL
Abbott	NULL
Laboratories	NULL
,	NULL
Groupe	NULL
Fournier	NULL
,	NULL
and	NULL
Parke-Davis	NULL
,	NULL
Warner-Lambert	NULL
Company	NULL
.	NULL

iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Methods	NULL
Page	NULL
2	NULL
Adhesion	NULL
of	NULL
circulating	NULL
leukocytes	NULL
to	NULL
the	NULL
endothelium	NULL
is	NULL
a	NULL
critical	NULL
early	NULL
step	NULL
in	NULL
atherogenesis	NULL
.	NULL

'~	NULL
``	NULL
This	NULL
process	NULL
depends	NULL
on	NULL
the	NULL
interaction	NULL
between	NULL
adhesion	NULL
molecules	NULL
on	NULL
the	NULL
endothelial	NULL
cell	NULL
(	NULL
EC	NULL
)	NULL
surface	NULL
and	NULL
their	NULL
cognate	NULL
ligands	NULL
on	NULL
leukocytes	NULL
.	NULL

These	NULL
EC	NULL
adhesion	NULL
molecules	NULL
include	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
(	NULL
VCAM-1	NULL
)	NULL
,	NULL
intercellular	NULL
adhesion	NULL
molecule	NULL
1	NULL
(	NULL
ICAM-1	NULL
)	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
P-selectin	NULL
.	NULL
``	NULL

''	NULL
Increased	NULL
adhesion	NULL
molecule	NULL
expression	NULL
by	NULL
ECs	NULL
in	NULL
human	NULL
atherosclerotic	NULL
lesions	NULL
may	NULL
contribute	NULL
to	NULL
further	NULL
leukocyte	NULL
recruitment	NULL
to	NULL
sites	NULL
of	NULL
atherosclerosis	NULL
.	NULL
``	NULL

Although	NULL
inducers	NULL
of	NULL
EC	NULL
adhesion	NULL
molecule	NULL
expression	NULL
,	NULL
such	NULL
as	NULL
the	NULL
inflammatory	NULL
mediators	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
-a	NULL
and	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-1	NULL
,	NULL
'°	NULL
have	NULL
received	NULL
much	NULL
attention	NULL
,	NULL
less	NULL
is	NULL
known	NULL
about	NULL
the	NULL
negative	NULL
regulation	NULL
of	NULL
adhesion	NULL
molecule	NULL
transcription	NULL
.	NULL

Such	NULL
understanding	NULL
may	NULL
provide	NULL
important	NULL
insight	NULL
into	NULL
plaque	NULL
formation	NULL
.	NULL

Certain	NULL
polyunsaturated	NULL
fatty	NULL
acids	NULL
,	NULL
for	NULL
example	NULL
,	NULL
docosahexaenoic	NULL
acid	NULL
(	NULL
DHA	NULL
)	NULL
,	NULL
can	NULL
inhibit	NULL
cytokine-induced	NULL
VCAM-1	NULL
expression	NULL
in	NULL
ECs	NULL
,	NULL
although	NULL
the	NULL
underlying	NULL
mechanism	NULL
remains	NULL
unclear	NULL
.	NULL
``	NULL

'	NULL
Interestingly	NULL
,	NULL
some	NULL
polyunsaturated	NULL
fatty	NULL
acids	NULL
can	NULL
activate	NULL
the	NULL
peroxisome	NULL
proliferator	NULL
,	NULL
activated	NULL
receptor-a	NULL
(	NULL
PPARa	NULL
)	NULL
,	NULL
a	NULL
nuclear	NULL
receptor	NULL
involved	NULL
with	NULL
transcriptional	NULL
responses	NULL
to	NULL
fatty	NULL
acids	NULL
.	NULL

Fibric	NULL
acid	NULL
derivatives	NULL
,	NULL
such	NULL
as	NULL
fenofibrate	NULL
,	NULL
are	NULL
also	NULL
thought	NULL
to	NULL
act	NULL
as	NULL
specific	NULL
activators	NULL
for	NULL
PPARa	NULL
.	NULL

'~	NULL
``	NULL
*	NULL
In	NULL
addition	NULL
to	NULL
PPARa	NULL
,	NULL
the	NULL
PPAR	NULL
family	NULL
also	NULL
includes	NULL
PPARy	NULL
and	NULL
PPARS	NULL
.	NULL

PPARs	NULL
,	NULL
activated	NULL
by	NULL
binding	NULL
of	NULL
specific	NULL
agonists	NULL
,	NULL
form	NULL
heterodimers	NULL
with	NULL
the	NULL
retinoid	NULL
X	NULL
receptor	NULL
and	NULL
associate	NULL
with	NULL
PPAR	NULL
response	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
target	NULL
genes	NULL
whose	NULL
expression	NULL
they	NULL
regulate	NULL
.	NULL

!	NULL
``	NULL

We	NULL
have	NULL
demonstrated	NULL
expression	NULL
of	NULL
PPAR	NULL
in	NULL
human	NULL
ECs	NULL
and	NULL
identified	NULL
plasminogen	NULL
activator	NULL
inhibitor-1	NULL
as	NULL
a	NULL
potential	NULL
PPARy	NULL
target	NULL
gene	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

!	NULL
``	NULL

Although	NULL
PPARa	NULL
mRNA	NULL
expression	NULL
in	NULL
human	NULL
ECs	NULL
has	NULL
been	NULL
reported	NULL
,	NULL
``	NULL
``	NULL
its	NULL
role	NULL
in	NULL
EC	NULL
biology	NULL
,	NULL
including	NULL
candidate	NULL
target	NULL
genes	NULL
,	NULL
remains	NULL
essentially	NULL
unexplored	NULL
.	NULL

We	NULL
hypothesized	NULL
that	NULL
PPARa	NULL
might	NULL
regulate	NULL
VCAM-1	NULL
expression	NULL
in	NULL
human	NULL
ECs	NULL
,	NULL
thus	NULL
potentially	NULL
modulating	NULL
leukocyte	NULL
adhesion	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
presence	NULL
of	NULL
PPARa	NULL
in	NULL
human	NULL
ECs	NULL
,	NULL
studying	NULL
the	NULL
effect	NULL
of	NULL
well-established	NULL
PPARa	NULL
and	NULL
PPARy	NULL
activators	NULL
on	NULL
adhesion	NULL
molecule	NULL
expression	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Immunohistochemistry	NULL
of	NULL
Human	NULL
Carotid	NULL
Artery	NULL
Specimens	NULL
Staining	NULL
for	NULL
PPARa	NULL
was	NULL
performed	NULL
on	NULL
acetone-fixed	NULL
serial	NULL
cryostat	NULL
sections	NULL
of	NULL
human	NULL
carotid	NULL
arteries	NULL
(	NULL
protocols	NULL
approved	NULL
by	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Institutional	NULL
Review	NULL
Board	NULL
)	NULL
with	NULL
a	NULL
polyclonal	NULL
goat	NULL
anti-human	NULL
PPARa	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
.	NULL

ECs	NULL
were	NULL
identified	NULL
by	NULL
staining	NULL
with	NULL
anti-CD31	NULL
antibodies	NULL
(	NULL
Dako	NULL
)	NULL
.	NULL

Sections	NULL
were	NULL
blocked	NULL
with	NULL
PBS/5	NULL
%	NULL
serum	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
appropriate	NULL
biotinylated	NULL
secondary	NULL
antibody	NULL
(	NULL
Vector	NULL
Laboratories	NULL
)	NULL
,	NULL
then	NULL
avidin-biotinperoxidase	NULL
complex	NULL
(	NULL
Vectastain	NULL
ABC	NULL
kit	NULL
)	NULL
.	NULL

Antibody	NULL
binding	NULL
was	NULL
visualized	NULL
with	NULL
True	NULL
Blue	NULL
peroxidase	NULL
substrate	NULL
(	NULL
Kirkegaard	NULL
&	NULL
Perry	NULL
Laboratories	NULL
)	NULL
and	NULL
counterstained	NULL
with	NULL
Gill	NULL
's	NULL
hematoxylin	NULL
or	NULL
contrast	NULL
red	NULL
(	NULL
Kirkegaard	NULL
&	NULL
Perry	NULL
Laboratories	NULL
)	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
3	NULL
Cell	NULL
Culture	NULL
Human	NULL
saphenous	NULL
vein	NULL
ECs	NULL
were	NULL
isolated	NULL
from	NULL
explants	NULL
from	NULL
unused	NULL
portions	NULL
of	NULL
saphenous	NULL
veins	NULL
harvested	NULL
at	NULL
coronary	NULL
artery	NULL
bypass	NULL
surgery	NULL
.	NULL

Cells	NULL
,	NULL
cultured	NULL
as	NULL
described	NULL
before	NULL
,	NULL
``	NULL
!	NULL

were	NULL
>	NULL
99	NULL
%	NULL
von	NULL
Willebrand	NULL
factor-positive	NULL
by	NULL
flow	NULL
cytometry	NULL
,	NULL
exhibited	NULL
typical	NULL
EC	NULL
cobblestone	NULL
growth	NULL
pattern	NULL
,	NULL
and	NULL
were	NULL
of	NULL
low	NULL
passage	NULL
number	NULL
(	NULL
p2-5	NULL
)	NULL
.	NULL

Bovine	NULL
aortic	NULL
ECs	NULL
(	NULL
BAECs	NULL
)	NULL
and	NULL
human	NULL
fibroblasts	NULL
were	NULL
cultured	NULL
in	NULL
DMEM	NULL
(	NULL
Biowhittaker	NULL
)	NULL
containing	NULL
1	NULL
%	NULL
glutamine	NULL
,	NULL
1	NULL
%	NULL
penicillin-streptomycin	NULL
,	NULL
and	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

The	NULL
hematopoietic	NULL
cell	NULL
line	NULL
U937	NULL
was	NULL
cultured	NULL
in	NULL
RPMI	NULL
medium	NULL
(	NULL
Biowhittaker	NULL
)	NULL
containing	NULL
1	NULL
%	NULL
glutamine	NULL
,	NULL
1	NULL
%	NULL
penicillin-streptomycin	NULL
,	NULL
and	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Preparation	NULL
of	NULL
Nuclear	NULL
and	NULL
Cytosolic	NULL
Extracts	NULL
and	NULL
Western	NULL
Blot	NULL
Analysis	NULL
For	NULL
Western	NULL
blotting	NULL
,	NULL
nuclear	NULL
and	NULL
cytosolic	NULL
extracts	NULL
of	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
Processed	NULL
samples	NULL
were	NULL
applied	NULL
to	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
(	NULL
Millipore	NULL
)	NULL
by	NULL
use	NULL
of	NULL
semidry	NULL
blotting	NULL
.	NULL
``	NULL

Membranes	NULL
were	NULL
treated	NULL
overnight	NULL
with	NULL
TBS-Tween/5	NULL
%	NULL
dry	NULL
milk	NULL
and	NULL
incubated	NULL
with	NULL
goat	NULL
anti-human	NULL
PPARa	NULL
antibodies	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
membranes	NULL
were	NULL
incubated	NULL
with	NULL
horseradish	NULL
peroxidase-	NULL
conjugated	NULL
rabbit	NULL
anti-goat	NULL
monoclonal	NULL
antibodies	NULL
.	NULL

Antigen	NULL
detection	NULL
was	NULL
performed	NULL
via	NULL
chemiluminescence	NULL
(	NULL
NEN	NULL
)	NULL
;	NULL
Nuclear	NULL
extracts	NULL
from	NULL
human	NULL
fibroblasts	NULL
transfected	NULL
with	NULL
a	NULL
PPARa	NULL
expression	NULL
construct	NULL
(	NULL
provided	NULL
by	NULL
Dr	NULL
Bruce	NULL
Spiegelman	NULL
,	NULL
Dana	NULL
Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
)	NULL
served	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

Cell-Surface	NULL
Enzyme	NULL
Immunoassays	NULL
For	NULL
determination	NULL
of	NULL
cell-surface	NULL
expression	NULL
of	NULL
adhesion	NULL
molecules	NULL
,	NULL
ECs	NULL
were	NULL
pretreated	NULL
with	NULL
PPAR	NULL
activators	NULL
[	NULL
PPARa	NULL
activators	NULL
:	NULL
fenofibrate	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
WY	NULL
14643	NULL
(	NULL
Biomol	NULL
)	NULL
;	NULL
PPARy	NULL
activators	NULL
:	NULL
15-deoxy-~	NULL
'	NULL
>	NULL
'*-prostaglandin	NULL
J	NULL
;	NULL
(	NULL
15d-PGJ	NULL
;	NULL
)	NULL
(	NULL
Calbiochem	NULL
)	NULL
,	NULL
troglitazone	NULL
(	NULL
Parke-Davis	NULL
)	NULL
,	NULL
and	NULL
BRL	NULL
49653	NULL
(	NULL
SmithKline	NULL
Beecham	NULL
)	NULL
]	NULL
at	NULL
the	NULL
times	NULL
and	NULL
concentrations	NULL
indicated	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
the	NULL
specified	NULL
cytokines	NULL
(	NULL
8	NULL
hours	NULL
)	NULL
.	NULL

Enzyme	NULL
immunoassay	NULL
(	NULL
EIA	NULL
)	NULL
was	NULL
performed	NULL
by	NULL
incubating	NULL
EC	NULL
monolayers	NULL
first	NULL
with	NULL
specific	NULL
monoclonal	NULL
antibodies	NULL
against	NULL
VCAM-1	NULL
(	NULL
E1/6	NULL
)	NULL
,	NULL
ICAM-1	NULL
(	NULL
HU5/3	NULL
)	NULL
,	NULL
or	NULL
E-selectin	NULL
(	NULL
H18/7	NULL
)	NULL
,	NULL
then	NULL
with	NULL
biotinylated	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
Vector	NULL
Laboratories	NULL
)	NULL
,	NULL
and	NULL
finally	NULL
with	NULL
streptavidin-alkaline	NULL
phosphatase	NULL
(	NULL
Zymed	NULL
Laboratories	NULL
)	NULL
.	NULL

(	NULL
All	NULL
monoclonal	NULL
antibodies	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr	NULL
Michael	NULL
Gimbrone	NULL
,	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
in	NULL
PBS/1	NULL
%	NULL
BSA	NULL
after	NULL
each	NULL
incubation	NULL
step	NULL
,	NULL
and	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
cellular	NULL
monolayer	NULL
was	NULL
ensured	NULL
by	NULL
phase-contrast	NULL
microscopy	NULL
.	NULL

Surface	NULL
expression	NULL
of	NULL
each	NULL
adhesion	NULL
molecule	NULL
was	NULL
measured	NULL
spectrophotometrically	NULL
at	NULL
410	NULL
nm	NULL
15	NULL
to	NULL
30	NULL
minutes	NULL
after	NULL
addition	NULL
of	NULL
the	NULL
chromogenic	NULL
substrate	NULL
(	NULL
para-nitrophenylphosphate	NULL
,	NULL
Sigma	NULL
)	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
for	NULL
each	NULL
condition	NULL
.	NULL

Adhesion	NULL
Assay	NULL
ECs	NULL
were	NULL
grown	NULL
to	NULL
confluence	NULL
in	NULL
96-well	NULL
plates	NULL
,	NULL
pretreated	NULL
with	NULL
PPARa	NULL
activators	NULL
for	NULL
24	NULL
hours	NULL
,	NULL
and	NULL
stimulated	NULL
with	NULL
TNF-a	NULL
for	NULL
8	NULL
hours	NULL
,	NULL
then	NULL
adhesion	NULL
assays	NULL
were	NULL
performed	NULL
.	NULL

'*	NULL
Briefly	NULL
,	NULL
U937	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
2',7	NULL
``	NULL
-bis	NULL
(	NULL
2-carboxy	NULL
)	NULL
-fluorescein	NULL
acetoxymethyl	NULL
ester	NULL
(	NULL
Molecular	NULL
Probes	NULL
)	NULL
and	NULL
then	NULL
added	NULL
,	NULL
under	NULL
rolling	NULL
conditions	NULL
(	NULL
63	NULL
rpm	NULL
,	NULL
23°C	NULL
,	NULL
15	NULL
minutes	NULL
)	NULL
,	NULL
to	NULL
a	NULL
rinsed	NULL
EC	NULL
monolayer	NULL
(	NULL
210°	NULL
cells/mL	NULL
)	NULL
in	NULL
RPMI	NULL
medium/10	NULL
%	NULL
FCS/1	NULL
mmol/L	NULL
CaCl	NULL
»	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
4	NULL
Nonadherent	NULL
cells	NULL
were	NULL
removed	NULL
by	NULL
inverting	NULL
the	NULL
plate	NULL
under	NULL
rotation	NULL
(	NULL
20	NULL
minutes	NULL
)	NULL
.	NULL

After	NULL
solubilization	NULL
of	NULL
well	NULL
contents	NULL
,	NULL
fluorescence	NULL
intensity	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
microtiter	NULL
plate	NULL
fluorimeter	NULL
(	NULL
Pandex	NULL
,	NULL
FCA	NULL
)	NULL
.	NULL

A	NULL
standard	NULL
curve	NULL
using	NULL
dilutions	NULL
of	NULL
labeled	NULL
U937	NULL
cells	NULL
was	NULL
determined	NULL
,	NULL
and	NULL
results	NULL
were	NULL
expressed	NULL
as	NULL
cells/cm	NULL
.	NULL

RNA	NULL
Extraction	NULL
and	NULL
Northern	NULL
Blot	NULL
Analysis	NULL
For	NULL
Northern	NULL
blot	NULL
experiments	NULL
,	NULL
human	NULL
ECs	NULL
were	NULL
pretreated	NULL
with	NULL
PPARa	NULL
activators	NULL
for	NULL
24	NULL
hours	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
the	NULL
specified	NULL
cytokines	NULL
for	NULL
3	NULL
hours	NULL
.	NULL

Total	NULL
RNA	NULL
(	NULL
10	NULL
``	NULL
cells	NULL
)	NULL
was	NULL
isolated	NULL
by	NULL
the	NULL
guanidinium	NULL
thiocyanate-phenol-chloroform	NULL
method	NULL
(	NULL
RNAzol	NULL
,	NULL
Tel-Test	NULL
)	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
RNA	NULL
used	NULL
in	NULL
standard	NULL
Northern	NULL
blot	NULL
analysis	NULL
with	NULL
a	NULL
VCAM-1	NULL
probe	NULL
.	NULL

VCAM-1	NULL
mRNA	NULL
half-life	NULL
was	NULL
determined	NULL
by	NULL
stimulating	NULL
ECs	NULL
with	NULL
TNF-a	NULL
for	NULL
3	NULL
hours	NULL
before	NULL
blocking	NULL
transcription	NULL
by	NULL
treatment	NULL
with	NULL
actinomycin	NULL
D	NULL
5	NULL
ug/L	NULL
.	NULL

Cells	NULL
then	NULL
received	NULL
fenofibrate	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
;	NULL
mRNA	NULL
levels	NULL
were	NULL
compared	NULL
with	NULL
those	NULL
of	NULL
untreated	NULL
cells	NULL
.	NULL

Transient	NULL
Transfections	NULL
To	NULL
investigate	NULL
the	NULL
effect	NULL
of	NULL
PPARa	NULL
activators	NULL
on	NULL
VCAM-1	NULL
promoter	NULL
activity	NULL
,	NULL
we	NULL
transiently	NULL
transfected	NULL
BAECs	NULL
with	NULL
a	NULL
series	NULL
of	NULL
deletional	NULL
VCAM-1	NULL
promoter	NULL
constructs	NULL
,	NULL
all	NULL
containing	NULL
the	NULL
chloramphenicol	NULL
acetylItransferase	NULL
(	NULL
CAT	NULL
)	NULL
reporter	NULL
.	NULL
``	NULL

[	NULL
-755	NULL
]	NULL
FO.CAT	NULL
is	NULL
the	NULL
putative	NULL
full-length	NULL
human	NULL
VCAM-1	NULL
promoter	NULL
containing	NULL
AP-1	NULL
,	NULL
GATA	NULL
,	NULL
and	NULL
binding	NULL
sites	NULL
.	NULL

[	NULL
-28JF3.CAT	NULL
lacks	NULL
the	NULL
AP-1	NULL
and	NULL
GATA	NULL
sites	NULL
but	NULL
retains	NULL
NF-xB	NULL
binding	NULL
sites	NULL
.	NULL

[	NULL
-44	NULL
]	NULL
F4.CAT	NULL
lacks	NULL
NF-xB	NULL
binding	NULL
sites	NULL
(	NULL
Figure	NULL
5A	NULL
)	NULL
.	NULL

BAECs	NULL
,	NULL
which	NULL
are	NULL
more	NULL
easily	NULL
transfectable	NULL
than	NULL
human	NULL
ECs	NULL
,	NULL
were	NULL
cotransfected	NULL
via	NULL
calcium	NULL
phosphate	NULL
precipitation	NULL
``	NULL
with	NULL
each	NULL
reporter	NULL
construct	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
and	NULL
a	NULL
pCMV.B-GAL	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
(	NULL
48	NULL
hours	NULL
after	NULL
transfection	NULL
)	NULL
with	NULL
TNF-a	NULL
10	NULL
ug/L	NULL
with	NULL
or	NULL
without	NULL
fenofibrate	NULL
100	NULL
umol/L	NULL
.	NULL

BAECs	NULL
were	NULL
then	NULL
harvested	NULL
after	NULL
36	NULL
hours	NULL
,	NULL
and	NULL
lysates	NULL
were	NULL
subjected	NULL
to	NULL
CAT	NULL
and	NULL
B-galactosidase	NULL
assay	NULL
(	NULL
Tropix	NULL
)	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Normalized	NULL
CAT	NULL
activity	NULL
was	NULL
calculated	NULL
as	NULL
the	NULL
ratio	NULL
of	NULL
CAT	NULL
activity	NULL
to	NULL
B-galactosidase	NULL
activity	NULL
.	NULL

Results	NULL
for	NULL
each	NULL
reporter	NULL
construct	NULL
were	NULL
expressed	NULL
as	NULL
multiples	NULL
of	NULL
induction	NULL
compared	NULL
with	NULL
transfected	NULL
,	NULL
unstimulated	NULL
cells	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
For	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
,	NULL
human	NULL
ECs	NULL
were	NULL
preincubated	NULL
for	NULL
24	NULL
hours	NULL
with	NULL
fenofibrate	NULL
100	NULL
umol/L	NULL
and	NULL
then	NULL
stimulated	NULL
for	NULL
2	NULL
hours	NULL
with	NULL
TNF-a	NULL
10	NULL
ug/L	NULL
before	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
(	NULL
CCTGGGTTTCCCCT-TGAAGGGATTTCCCTCC	NULL
)	NULL
(	NULL
Genosys	NULL
Biotechnologies	NULL
)	NULL
spanning	NULL
the	NULL
2	NULL
tandem	NULL
NF-KB	NULL
sites	NULL
(	NULL
as	NULL
underlined	NULL
above	NULL
)	NULL
in	NULL
the	NULL
human	NULL
VCAM-1	NULL
promoter	NULL
was	NULL
end-labeled	NULL
with	NULL
[	NULL
y-	NULL
``	NULL
P	NULL
]	NULL
JATP	NULL
(	NULL
3000	NULL
Ci/mmol	NULL
)	NULL
by	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
and	NULL
purified	NULL
(	NULL
Sephadex	NULL
G-25	NULL
columns	NULL
,	NULL
Pharmacia	NULL
LKB	NULL
Biotechnology	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
labeled	NULL
NF-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
under	NULL
standard	NULL
conditions	NULL
.	NULL
``	NULL

''	NULL
In	NULL
the	NULL
indicated	NULL
experiments	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
anti-p50	NULL
[	NULL
polyclonal	NULL
rabbit	NULL
anti-p50	NULL
(	NULL
NLS	NULL
)	NULL
X	NULL
,	NULL
Santa	NULL
Cruz	NULL
]	NULL
or	NULL
anti-p65	NULL
(	NULL
polyclonal	NULL
rabbit	NULL
anti-p65	NULL
AX	NULL
,	NULL
Santa	NULL
Cruz	NULL
)	NULL
or	NULL
nonspecific	NULL
IgG	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
radiolabeled	NULL
NF-KB	NULL
probes	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
electrophoretically	NULL
separated	NULL
(	NULL
5	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gel	NULL
)	NULL
.	NULL

Specificity	NULL
was	NULL
Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
5	NULL
determined	NULL
by	NULL
addition	NULL
of	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
(	NULL
cold	NULL
)	NULL
NF-xB	NULL
oligonucleotide	NULL
to	NULL
the	NULL
nuclear	NULL
extracts	NULL
before	NULL
formation	NULL
of	NULL
DNA-protein	NULL
complexes	NULL
.	NULL

Assessment	NULL
of	NULL
Total	NULL
Protein	NULL
Synthesis	NULL
Total	NULL
protein	NULL
synthesis	NULL
was	NULL
assessed	NULL
as	NULL
incorporation	NULL
as	NULL
described	NULL
previously	NULL
.	NULL

``	NULL
!	NULL

Statistical	NULL
Analysis	NULL
Results	NULL
Results	NULL
of	NULL
the	NULL
experimental	NULL
studies	NULL
are	NULL
reported	NULL
as	NULL
mean+SEM	NULL
.	NULL

Differences	NULL
were	NULL
analyzed	NULL
by	NULL
1-way	NULL
ANOVA	NULL
followed	NULL
by	NULL
Fisher	NULL
's	NULL
protected	NULL
least	NULL
significant	NULL
difference	NULL
test	NULL
.	NULL

A	NULL
value	NULL
of	NULL
P	NULL
<	NULL
0.05	NULL
was	NULL
regarded	NULL
as	NULL
significant	NULL
.	NULL

Human	NULL
ECs	NULL
Express	NULL
PPARa	NULL
In	NULL
Vivo	NULL
and	NULL
In	NULL
Vitro	NULL
Immunohistochemistry	NULL
of	NULL
human	NULL
carotid	NULL
artery	NULL
specimens	NULL
(	NULL
n=6	NULL
)	NULL
revealed	NULL
PPARa	NULL
staining	NULL
in	NULL
the	NULL
EC	NULL
nuclei	NULL
(	NULL
Figure	NULL
1A	NULL
;	NULL
blue	NULL
staining	NULL
,	NULL
arrowheads	NULL
)	NULL
.	NULL

Parallel	NULL
sections	NULL
stained	NULL
with	NULL
goat	NULL
IgG	NULL
showed	NULL
no	NULL
immunostaining	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

ECs	NULL
were	NULL
identified	NULL
by	NULL
immunoreactive	NULL
CD31	NULL
(	NULL
platelet	NULL
and	NULL
endothelial	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
)	NULL
in	NULL
parallel	NULL
sections	NULL
(	NULL
Figure	NULL
1C	NULL
;	NULL
red	NULL
staining	NULL
)	NULL
.	NULL

To	NULL
demonstrate	NULL
PPARa	NULL
expression	NULL
in	NULL
vitro	NULL
in	NULL
a	NULL
homogeneous	NULL
population	NULL
of	NULL
human	NULL
ECs	NULL
,	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
cultured	NULL
human	NULL
saphenous	NULL
vein	NULL
ECs	NULL
was	NULL
performed	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
in	NULL
situ	NULL
findings	NULL
,	NULL
PPARa	NULL
protein	NULL
was	NULL
detected	NULL
in	NULL
nuclear	NULL
but	NULL
not	NULL
cytosolic	NULL
fractions	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
the	NULL
detected	NULL
band	NULL
was	NULL
confirmed	NULL
by	NULL
comigration	NULL
with	NULL
a	NULL
band	NULL
from	NULL
fibroblasts	NULL
transfected	NULL
with	NULL
a	NULL
PPARa	NULL
expression	NULL
construct	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
;	NULL
untransfected	NULL
fibroblasts	NULL
reveal	NULL
no	NULL
such	NULL
band	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

PPARa	NULL
but	NULL
Not	NULL
PPARy	NULL
Activators	NULL
Reduce	NULL
EC	NULL
Surface	NULL
Expression	NULL
of	NULL
VCAM-1	NULL
As	NULL
expected	NULL
,	NULL
cell	NULL
surface	NULL
EIAs	NULL
of	NULL
human	NULL
ECs	NULL
revealed	NULL
a	NULL
marked	NULL
increase	NULL
of	NULL
VCAM-1	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
TNF-a	NULL
10	NULL
sg/L	NULL
.	NULL

Pretreatment	NULL
of	NULL
ECs	NULL
with	NULL
the	NULL
PPARa	NULL
activator	NULL
fenofibrate	NULL
100	NULL
smol/L	NULL
or	NULL
WY14643	NULL
250	NULL
smol/L	NULL
reduced	NULL
VCAM-1	NULL
expression	NULL
levels	NULL
significantly	NULL
,	NULL
to	NULL
33+9	NULL
%	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
or	NULL
52+2	NULL
%	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
of	NULL
TNF-a-stimulated	NULL
cells	NULL
,	NULL
respectively	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

None	NULL
of	NULL
3	NULL
different	NULL
PPARy	NULL
activators	NULL
(	NULL
troglitazone	NULL
,	NULL
10	NULL
smol/L	NULL
;	NULL
15d-PGJ	NULL
;	NULL
,	NULL
10	NULL
smol/L	NULL
;	NULL
or	NULL
BRLA9653	NULL
,	NULL
10	NULL
smol/L	NULL
)	NULL
;	NULL
significantly	NULL
affected	NULL
TNF-a-induced	NULL
VCAM-1	NULL
expression	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
unstimulated	NULL
human	NULL
ECs	NULL
with	NULL
PPARa	NULL
or	NULL
PPARy	NULL
activators	NULL
did	NULL
not	NULL
alter	NULL
VCAM-1	NULL
expression	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Fenofibrate	NULL
did	NULL
not	NULL
affect	NULL
EC	NULL
viability	NULL
(	NULL
>	NULL
95	NULL
%	NULL
excluded	NULL
trypan	NULL
blue	NULL
)	NULL
or	NULL
total	NULL
protein	NULL
synthesis	NULL
(	NULL
263+5x	NULL
10°	NULL
epm/cm	NULL
>	NULL
well	NULL
in	NULL
TNF-a-treated	NULL
cells	NULL
versus	NULL
283+22x10°	NULL
well	NULL
in	NULL
TNF-a-	NULL
and	NULL
fenofibrate-treated	NULL
cells	NULL
;	NULL
P=NS	NULL
)	NULL
.	NULL

Neither	NULL
PPARa	NULL
nor	NULL
PPARy	NULL
activators	NULL
significantly	NULL
reduced	NULL
the	NULL
TNF-a-induced	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
ICAM-1	NULL
(	NULL
Figure	NULL
2B	NULL
,	NULL
solid	NULL
bars	NULL
)	NULL
or	NULL
E-selectin	NULL
(	NULL
Figure	NULL
2B	NULL
,	NULL
open	NULL
bars	NULL
)	NULL
in	NULL
ECs	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
6	NULL
Fenofibrate	NULL
Reduces	NULL
Cytokine-Induced	NULL
VCAM-1	NULL
Expression	NULL
in	NULL
a	NULL
Time-	NULL
and	NULL
Concentration-Dependent	NULL
Manner	NULL
To	NULL
investigate	NULL
the	NULL
time-	NULL
and	NULL
concentration-dependence	NULL
of	NULL
PPARa	NULL
activator	NULL
treatment	NULL
on	NULL
VCAM-1	NULL
expression	NULL
,	NULL
human	NULL
ECs	NULL
were	NULL
pretreated	NULL
with	NULL
fenofibrate	NULL
for	NULL
different	NULL
times	NULL
or	NULL
concentrations	NULL
before	NULL
stimulation	NULL
with	NULL
TNF-a	NULL
and	NULL
subsequent	NULL
EIA	NULL
determination	NULL
of	NULL
VCAM-1	NULL
expression	NULL
.	NULL

Inhibition	NULL
of	NULL
TNF-a-induced	NULL
VCAM-1	NULL
expression	NULL
depended	NULL
on	NULL
the	NULL
time	NULL
of	NULL
fenofibrate	NULL
exposure	NULL
,	NULL
with	NULL
a	NULL
maximal	NULL
reduction	NULL
after	NULL
24	NULL
hours	NULL
of	NULL
fenofibrate	NULL
pretreatment	NULL
(	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
fenofibrate	NULL
inhibited	NULL
VCAM-1	NULL
expression	NULL
in	NULL
human	NULL
ECs	NULL
induced	NULL
by	NULL
TNF-a	NULL
(	NULL
Figure	NULL
2D	NULL
,	NULL
solid	NULL
bars	NULL
)	NULL
or	NULL
IL-1a	NULL
(	NULL
Figure	NULL
2D	NULL
,	NULL
open	NULL
bars	NULL
)	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
with	NULL
a	NULL
maximal	NULL
reduction	NULL
at	NULL
100	NULL
umol/L	NULL
fenofibrate	NULL
.	NULL

PPARa	NULL
Activators	NULL
Inhibit	NULL
the	NULL
Adhesion	NULL
of	NULL
Monocyte-Like	NULL
Cells	NULL
on	NULL
Human	NULL
ECs	NULL
To	NULL
investigate	NULL
the	NULL
potential	NULL
functional	NULL
relevance	NULL
of	NULL
PPARa	NULL
activator-reduced	NULL
VCAM-1	NULL
expression	NULL
in	NULL
human	NULL
ECs	NULL
,	NULL
we	NULL
performed	NULL
an	NULL
in	NULL
vitro	NULL
adhesion	NULL
assay	NULL
using	NULL
fluorescently	NULL
labeled	NULL
U937	NULL
cells	NULL
and	NULL
monolayers	NULL
of	NULL
human	NULL
ECs	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
EC	NULL
monolayer	NULL
with	NULL
TNF-a	NULL
increased	NULL
the	NULL
number	NULL
of	NULL
adherent	NULL
cells	NULL
from	NULL
9.1+1.5x10°	NULL
cells/cm	NULL
``	NULL
to	NULL
73.2+2.4x10°	NULL
cells/cm	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

Pretreatment	NULL
of	NULL
EC	NULL
's	NULL
with	NULL
fenofibrate	NULL
or	NULL
WY	NULL
14643	NULL
before	NULL
TNF-a	NULL
stimulation	NULL
reduced	NULL
U937	NULL
cell	NULL
adhesion	NULL
significantly	NULL
,	NULL
to	NULL
36.7+2.2x10°	NULL
cells/cm	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
or	NULL
37.3+4.3x10°	NULL
cells/cm	NULL
``	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
respectively	NULL
(	NULL
Figure3A	NULL
and	NULL
3B	NULL
)	NULL
.	NULL

Preincubation	NULL
of	NULL
TNF-a-stimulated	NULL
ECs	NULL
with	NULL
blocking	NULL
anti-	NULL
VCAM	NULL
monoclonal	NULL
antibody	NULL
inhibited	NULL
U937	NULL
cell	NULL
adhesion	NULL
almost	NULL
completely	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

PPARa	NULL
Activators	NULL
Reduce	NULL
Cytokine-Induced	NULL
VCAM-1	NULL
mRNA	NULL
Levels	NULL
in	NULL
Human	NULL
ECs	NULL
Northern	NULL
blot	NULL
analysis	NULL
revealed	NULL
increased	NULL
VCAM-1	NULL
mRNA	NULL
levels	NULL
after	NULL
3	NULL
hours	NULL
of	NULL
stimulation	NULL
of	NULL
human	NULL
ECs	NULL
with	NULL
TNF-a	NULL
10	NULL
ug/L	NULL
,	NULL
which	NULL
could	NULL
be	NULL
inhibited	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
by	NULL
pretreatment	NULL
with	NULL
the	NULL
PPARa	NULL
activators	NULL
fenofibrate	NULL
or	NULL
WY14643	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
seen	NULL
when	NULL
ECs	NULL
were	NULL
stimulated	NULL
with	NULL
IL-1a	NULL
instead	NULL
of	NULL
TNF-a	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
actinomycin	NULL
D	NULL
,	NULL
fenofibrate	NULL
did	NULL
not	NULL
significantly	NULL
reduce	NULL
VCAM-1	NULL
mRNA	NULL
half-life	NULL
compared	NULL
with	NULL
control	NULL
cells	NULL
(	NULL
6.4+0.6	NULL
hours	NULL
in	NULL
control	NULL
cells	NULL
versus	NULL
6.4+1.1	NULL
hours	NULL
in	NULL
fenofibrate-stimulated	NULL
cells	NULL
,	NULL
P=NS	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
PPARa	NULL
activators	NULL
on	NULL
VCAM-1	NULL
does	NULL
not	NULL
result	NULL
from	NULL
altered	NULL
mRNA	NULL
stability	NULL
(	NULL
Figure	NULL
4B	NULL
)	NULL
.	NULL

Fenofibrate	NULL
Inhibits	NULL
TNF-a-Induced	NULL
VCAM-1	NULL
Promoter	NULL
Activity	NULL
To	NULL
determine	NULL
potential	NULL
sites	NULL
of	NULL
interaction	NULL
of	NULL
PPARa	NULL
activators	NULL
with	NULL
the	NULL
VCAM-1	NULL
promoter	NULL
,	NULL
we	NULL
performed	NULL
transient	NULL
transfections	NULL
of	NULL
various	NULL
deletional	NULL
VCAM-1	NULL
promoter	NULL
reporter	NULL
CAT	NULL
constructs	NULL
in	NULL
bovine	NULL
ECs	NULL
(	NULL
Figure	NULL
5A	NULL
)	NULL
.	NULL

After	NULL
stimulation	NULL
for	NULL
36	NULL
hours	NULL
,	NULL
CAT	NULL
activity	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
cotransfected	NULL
B-galactosidase	NULL
construct	NULL
,	NULL
was	NULL
measured	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
.	NULL

TNF-a	NULL
stimulation	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
full-length	NULL
promoter	NULL
construct	NULL
(	NULL
FO	NULL
)	NULL
led	NULL
to	NULL
a	NULL
5.9+1.6-fold	NULL
increase	NULL
in	NULL
normalized	NULL
promoter	NULL
activity	NULL
(	NULL
CAT/B-galactosidase	NULL
activity	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
fenofibrate	NULL
significantly	NULL
reduced	NULL
this	NULL
response	NULL
to	NULL
2.4+0.4-fold	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
compared	NULL
with	NULL
TNF-a-stimulated	NULL
cells	NULL
)	NULL
.	NULL

Transfection	NULL
studies	NULL
with	NULL
a	NULL
VCAM-1	NULL
promoter	NULL
deletion	NULL
construct	NULL
(	NULL
F3	NULL
)	NULL
containing	NULL
the	NULL
2	NULL
tandem	NULL
NF-	NULL
<	NULL
B	NULL
sites	NULL
,	NULL
but	NULL
lacking	NULL
the	NULL
AP-1	NULL
and	NULL
GATA	NULL
sites	NULL
,	NULL
revealed	NULL
similar	NULL
PPARa	NULL
agonist	NULL
responsiveness	NULL
.	NULL

Stimulation	NULL
of	NULL
transfected	NULL
Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
7	NULL
cells	NULL
with	NULL
TNF-a	NULL
enhanced	NULL
relative	NULL
CAT	NULL
activity	NULL
3.4+0.6-fold	NULL
;	NULL
treatment	NULL
with	NULL
fenofibrate	NULL
significantly	NULL
inhibited	NULL
this	NULL
increase	NULL
to	NULL
1.4+0.2	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
compared	NULL
with	NULL
TNF-a-stimulated	NULL
cells	NULL
)	NULL
.	NULL

Transfection	NULL
studies	NULL
with	NULL
the	NULL
VCAM-1	NULL
deletion	NULL
construct	NULL
(	NULL
F4	NULL
)	NULL
,	NULL
lacking	NULL
the	NULL
2	NULL
NF-xB	NULL
sites	NULL
,	NULL
revealed	NULL
no	NULL
change	NULL
in	NULL
relative	NULL
CAT	NULL
activity	NULL
after	NULL
treatment	NULL
with	NULL
TNF-a	NULL
or	NULL
fenofibrate	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
all	NULL
constructs	NULL
,	NULL
treatment	NULL
with	NULL
fenofibrate	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
relative	NULL
CAT	NULL
activity	NULL
compared	NULL
with	NULL
control	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
absence	NULL
of	NULL
consensus	NULL
PPAR	NULL
response	NULL
elements	NULL
in	NULL
the	NULL
VCAM	NULL
promoter	NULL
.	NULL

Fenofibrate	NULL
Inhibits	NULL
a-Induced	NULL
NF-xB	NULL
Activation	NULL
EMSAs	NULL
that	NULL
used	NULL
radiolabeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
2	NULL
tandem	NULL
NF-B	NULL
sites	NULL
in	NULL
the	NULL
VCAM-1	NULL
promoter	NULL
were	NULL
performed	NULL
to	NULL
investigate	NULL
whether	NULL
PPARa	NULL
activators	NULL
inhibit	NULL
NF-	NULL
<	NULL
B	NULL
activation	NULL
.	NULL

Fenofibrate	NULL
decreased	NULL
the	NULL
amount	NULL
of	NULL
shifted	NULL
complexes	NULL
induced	NULL
by	NULL
TNF-a	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
PPARa	NULL
,	NULL
activators	NULL
directly	NULL
inhibit	NULL
NF-xB	NULL
activation	NULL
(	NULL
Figure	NULL
5C	NULL
)	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
these	NULL
findings	NULL
,	NULL
supershift	NULL
analysis	NULL
was	NULL
performed	NULL
to	NULL
define	NULL
fenofibrate	NULL
effects	NULL
on	NULL
the	NULL
NF-KB	NULL
transcriptional	NULL
complex	NULL
(	NULL
Figure	NULL
5C	NULL
)	NULL
.	NULL

As	NULL
described	NULL
by	NULL
others	NULL
,	NULL
TNF-a-induced	NULL
NF-KB	NULL
activation	NULL
involves	NULL
the	NULL
p50	NULL
and	NULL
p65	NULL
subunits	NULL
.	NULL

Fenofibrate	NULL
treatment	NULL
of	NULL
similarly	NULL
stimulated	NULL
ECs	NULL
resulted	NULL
in	NULL
a	NULL
parallel	NULL
decrease	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
supershifted	NULL
p50	NULL
and	NULL
p65	NULL
complexes	NULL
.	NULL

Discussion	NULL
The	NULL
present	NULL
study	NULL
reports	NULL
expression	NULL
of	NULL
PPARa	NULL
in	NULL
ECs	NULL
of	NULL
human	NULL
arteries	NULL
and	NULL
reduction	NULL
of	NULL
cytokine-induced	NULL
VCAM-1	NULL
expression	NULL
by	NULL
PPARa	NULL
agonists	NULL
through	NULL
inhibition	NULL
of	NULL
NF-B	NULL
.	NULL

This	NULL
inhibition	NULL
of	NULL
VCAM-1	NULL
expression	NULL
by	NULL
PPARa	NULL
activators	NULL
decreased	NULL
adhesion	NULL
of	NULL
monocyte-like	NULL
cells	NULL
to	NULL
stimulated	NULL
ECs	NULL
.	NULL

PPARy	NULL
activators	NULL
exhibited	NULL
no	NULL
such	NULL
effects	NULL
.	NULL

Initially	NULL
,	NULL
PPARa	NULL
was	NULL
thought	NULL
to	NULL
be	NULL
limited	NULL
to	NULL
tissues	NULL
such	NULL
as	NULL
liver	NULL
and	NULL
fat	NULL
,	NULL
in	NULL
which	NULL
it	NULL
participates	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
lipid	NULL
,	NULL
and	NULL
in	NULL
particular	NULL
fatty	NULL
acid	NULL
,	NULL
metabolism	NULL
.	NULL
``	NULL

A	NULL
recent	NULL
study	NULL
demonstrated	NULL
PPARa	NULL
expression	NULL
in	NULL
human	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
with	NULL
inhibition	NULL
of	NULL
IL-6	NULL
,	NULL
cyclooxygenase-	NULL
2	NULL
,	NULL
and	NULL
prostaglandin	NULL
gene	NULL
expression	NULL
by	NULL
the	NULL
same	NULL
PPARa	NULL
activators	NULL
used	NULL
here	NULL
(	NULL
W	NULL
Y14643	NULL
,	NULL
fenofibrate	NULL
)	NULL
.	NULL
``	NULL

''	NULL
Human	NULL
ECs	NULL
,	NULL
like	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
,	NULL
express	NULL
both	NULL
PPARa	NULL
and	NULL
'*	NULL
with	NULL
each	NULL
PPAR	NULL
probably	NULL
having	NULL
unique	NULL
effects	NULL
relevant	NULL
to	NULL
vascular	NULL
biology	NULL
in	NULL
these	NULL
cellular	NULL
settings	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
PPARy	NULL
expression	NULL
in	NULL
ECs	NULL
and	NULL
suggested	NULL
a	NULL
role	NULL
of	NULL
PPAR	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
plasminogen	NULL
activator	NULL
inhibitor-1	NULL
gene	NULL
expression	NULL
.	NULL
``	NULL

''	NULL
We	NULL
report	NULL
here	NULL
that	NULL
PPARy	NULL
activation	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
adhesion	NULL
molecule	NULL
expression	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
2	NULL
different	NULL
established	NULL
PPARa	NULL
activators	NULL
,	NULL
fenofibrate	NULL
and	NULL
WY	NULL
14643	NULL
,	NULL
inhibit	NULL
cytokine-induced	NULL
VCAM-1	NULL
expression	NULL
in	NULL
ECs	NULL
.	NULL

These	NULL
agents	NULL
probably	NULL
act	NULL
in	NULL
ECs	NULL
by	NULL
activating	NULL
PPARa	NULL
,	NULL
.	NULL

Both	NULL
of	NULL
these	NULL
agonists	NULL
have	NULL
high	NULL
binding	NULL
affinities	NULL
to	NULL
PPARa	NULL
while	NULL
selectively	NULL
interacting	NULL
with	NULL
PPARa	NULL
,	NULL
with	NULL
little	NULL
to	NULL
no	NULL
activity	NULL
on	NULL
other	NULL
PPAR	NULL
isoforms	NULL
.	NULL
'	NULL

>	NULL
25	NULL
The	NULL
fibrates	NULL
used	NULL
here	NULL
produced	NULL
inhibitory	NULL
effects	NULL
at	NULL
concentrations	NULL
similar	NULL
to	NULL
those	NULL
that	NULL
induced	NULL
established	NULL
PPARa	NULL
response	NULL
genes	NULL
,	NULL
eg	NULL
,	NULL
apolipoprotein	NULL
A-IL	NULL
.	NULL

*	NULL
``	NULL
In	NULL
contrast	NULL
,	NULL
various	NULL
PPARy	NULL
activators	NULL
,	NULL
among	NULL
them	NULL
the	NULL
highly	NULL
specific	NULL
PPARy	NULL
agonist	NULL
BRLA9653	NULL
,	NULL
'	NULL
>	NULL
°	NULL
added	NULL
either	NULL
before	NULL
or	NULL
after	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
cytokine	NULL
treatment	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
VCAM-1	NULL
levels	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
8	NULL
Therefore	NULL
,	NULL
PPARy	NULL
activation	NULL
by	NULL
PPARa	NULL
agonists	NULL
seems	NULL
an	NULL
unlikely	NULL
explanation	NULL
for	NULL
our	NULL
results	NULL
.	NULL

The	NULL
reduction	NULL
of	NULL
VCAM-1	NULL
expression	NULL
by	NULL
PPARa	NULL
activators	NULL
appears	NULL
at	NULL
a	NULL
transcriptional	NULL
level	NULL
because	NULL
fenofibrate	NULL
did	NULL
not	NULL
alter	NULL
VCAM-1	NULL
mRNA	NULL
half-life	NULL
but	NULL
did	NULL
inhibit	NULL
TNF-a-induced	NULL
VCAM-1	NULL
promoter	NULL
activity	NULL
.	NULL

This	NULL
effect	NULL
appears	NULL
to	NULL
stem	NULL
from	NULL
inhibition	NULL
of	NULL
NF-	NULL
<	NULL
B	NULL
activation	NULL
,	NULL
as	NULL
suggested	NULL
by	NULL
the	NULL
reduction	NULL
of	NULL
CAT	NULL
activity	NULL
of	NULL
the	NULL
promoter	NULL
construct	NULL
lacking	NULL
binding	NULL
sites	NULL
(	NULL
[	NULL
-44	NULL
]	NULL
F4	NULL
)	NULL
and	NULL
gel	NULL
shift	NULL
assays	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
NF-xB	NULL
activation	NULL
by	NULL
PPARa	NULL
could	NULL
result	NULL
from	NULL
direct	NULL
interference	NULL
with	NULL
NF-xB	NULL
binding	NULL
to	NULL
the	NULL
VCAM-1	NULL
promoter	NULL
,	NULL
as	NULL
postulated	NULL
for	NULL
the	NULL
interaction	NULL
of	NULL
NF-xB	NULL
with	NULL
the	NULL
estrogen	NULL
receptor	NULL
.	NULL
``	NULL

Alternatively	NULL
,	NULL
the	NULL
inhibitory	NULL
effects	NULL
might	NULL
occur	NULL
through	NULL
competitive	NULL
binding	NULL
of	NULL
transcriptional	NULL
coactivators	NULL
by	NULL
PPARa	NULL
or	NULL
by	NULL
PPARa-induced	NULL
transcription	NULL
factors	NULL
.	NULL

Such	NULL
``	NULL
negative	NULL
crosstalk	NULL
``	NULL
has	NULL
been	NULL
suggested	NULL
between	NULL
other	NULL
nuclear	NULL
receptors	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
.	NULL

>	NULL
°	NULL
In	NULL
fact	NULL
,	NULL
one	NULL
such	NULL
coactivator	NULL
,	NULL
p300	NULL
,	NULL
involved	NULL
in	NULL
VCAM-1	NULL
expression	NULL
``	NULL
``	NULL
reportedly	NULL
interacts	NULL
with	NULL
PPARa	NULL
.	NULL

>	NULL
'	NULL
Our	NULL
data	NULL
also	NULL
do	NULL
not	NULL
exclude	NULL
a	NULL
PPARa	NULL
effect	NULL
on	NULL
IxB	NULL
or	NULL
an	NULL
effect	NULL
on	NULL
the	NULL
transcription	NULL
of	NULL
NF-xB	NULL
subunits	NULL
p30	NULL
and	NULL
p65	NULL
.	NULL

The	NULL
genes	NULL
encoding	NULL
ICAM-1	NULL
and	NULL
E-selectin	NULL
have	NULL
NF-KB	NULL
sites	NULL
in	NULL
their	NULL
promoter	NULL
;	NULL
nonetheless	NULL
,	NULL
PPARa	NULL
activators	NULL
did	NULL
not	NULL
alter	NULL
ICAM-1	NULL
or	NULL
E-selectin	NULL
expression	NULL
.	NULL

This	NULL
result	NULL
may	NULL
be	NULL
explained	NULL
in	NULL
several	NULL
ways	NULL
.	NULL

It	NULL
could	NULL
derive	NULL
from	NULL
the	NULL
distinct	NULL
nature	NULL
of	NULL
the	NULL
VCAM-1	NULL
promoter	NULL
,	NULL
either	NULL
its	NULL
NF-xB	NULL
sites	NULL
or	NULL
another	NULL
undefined	NULL
VCAM-1	NULL
transcriptional	NULL
element	NULL
,	NULL
``	NULL
ie	NULL
,	NULL
the	NULL
interferon	NULL
regulatory	NULL
factor-1	NULL
site	NULL
.	NULL

We	NULL
saw	NULL
no	NULL
effect	NULL
of	NULL
fenofibrate	NULL
on	NULL
the	NULL
known	NULL
TNF-a	NULL
induction	NULL
of	NULL
interferon	NULL
regulatory	NULL
factor-1	NULL
expression	NULL
in	NULL
ECs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL
``	NULL

Other	NULL
mechanisms	NULL
might	NULL
include	NULL
competition	NULL
for	NULL
transcriptional	NULL
coactivators	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Interestingly	NULL
,	NULL
retinoic	NULL
acid	NULL
,	NULL
acting	NULL
through	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
,	NULL
another	NULL
nuclear	NULL
receptor	NULL
family	NULL
member	NULL
,	NULL
also	NULL
appears	NULL
to	NULL
inhibit	NULL
activation	NULL
of	NULL
the	NULL
NF-xB	NULL
site	NULL
of	NULL
the	NULL
VCAM-1	NULL
promoter	NULL
,	NULL
but	NULL
not	NULL
NF-xB	NULL
activation	NULL
of	NULL
either	NULL
the	NULL
ICAM-1	NULL
or	NULL
E-selectin	NULL
promoters	NULL
.	NULL
``	NULL

Inhibition	NULL
of	NULL
VCAM-1	NULL
expression	NULL
in	NULL
human	NULL
ECs	NULL
by	NULL
PPARa	NULL
activators	NULL
,	NULL
with	NULL
a	NULL
consequent	NULL
decrease	NULL
in	NULL
monocyte	NULL
adherence	NULL
to	NULL
ECs	NULL
,	NULL
has	NULL
important	NULL
implications	NULL
regarding	NULL
atherogenic	NULL
mechanisms	NULL
as	NULL
well	NULL
as	NULL
the	NULL
treatment	NULL
of	NULL
atherosclerosis	NULL
,	NULL
especially	NULL
given	NULL
the	NULL
similarity	NULL
of	NULL
fenofibrate	NULL
concentrations	NULL
used	NULL
here	NULL
and	NULL
those	NULL
achieved	NULL
in	NULL
patients	NULL
.	NULL
``	NULL

''	NULL
Human	NULL
angiographic	NULL
studies	NULL
have	NULL
reported	NULL
that	NULL
fenofibrate	NULL
treatment	NULL
reduces	NULL
coronary	NULL
artery	NULL
stenoses	NULL
.	NULL
``	NULL

Epidemiological	NULL
``	NULL
®	NULL
as	NULL
well	NULL
as	NULL
experimental	NULL
work	NULL
``	NULL
``	NULL
suggests	NULL
that	NULL
the	NULL
intake	NULL
of	NULL
polyunsaturated	NULL
fatty	NULL
acids	NULL
,	NULL
some	NULL
of	NULL
them	NULL
also	NULL
known	NULL
PPARa	NULL
agonists	NULL
,	NULL
'	NULL
>	NULL
reduces	NULL
the	NULL
incidence	NULL
of	NULL
cardiovascular	NULL
events	NULL
.	NULL

Given	NULL
the	NULL
likely	NULL
involvement	NULL
of	NULL
VCAM-1	NULL
in	NULL
monocyte	NULL
recruitment	NULL
to	NULL
early	NULL
atherosclerotic	NULL
lesions	NULL
,	NULL
our	NULL
findings	NULL
suggest	NULL
PPARa	NULL
as	NULL
a	NULL
potential	NULL
mediator	NULL
of	NULL
critical	NULL
inflammatory	NULL
processes	NULL
in	NULL
the	NULL
vessel	NULL
wall	NULL
.	NULL

Acknowledgments	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
to	NULL
Dr	NULL
Marx	NULL
(	NULL
MA	NULL
2047/1-1	NULL
)	NULL
and	NULL
from	NULL
the	NULL
NIH/NHLBI	NULL
to	NULL
Dr	NULL
Libby	NULL
(	NULL
HL-48743	NULL
)	NULL
and	NULL
to	NULL
Dr	NULL
Plutzky	NULL
(	NULL
HL-03107	NULL
)	NULL
.	NULL

We	NULL
thank	NULL
Eugenia	NULL
Shvartz	NULL
,	NULL
Dr	NULL
Maria	NULL
Muszynski	NULL
,	NULL
Irina	NULL
Chulsky	NULL
,	NULL
Dr	NULL
Todd	NULL
Bourcier	NULL
,	NULL
Dr	NULL
Mitch	NULL
Lazar	NULL
,	NULL
and	NULL
Dr	NULL
Francis	NULL
W.	NULL
Luscinskas	NULL
for	NULL
their	NULL
assistance	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Page	NULL
9	NULL
Poole	NULL
JCF	NULL
,	NULL
Florey	NULL
HW	NULL
.	NULL

Changes	NULL
in	NULL
the	NULL
endothelium	NULL
of	NULL
the	NULL
aorta	NULL
and	NULL
the	NULL
behavior	NULL
of	NULL
macrophages	NULL
in	NULL
experimental	NULL
atheroma	NULL
of	NULL
rabbits	NULL
.	NULL

J	NULL
Pathol	NULL
Bacteriol	NULL
.	NULL

1958	NULL
;	NULL
75:245-253	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
13576305	NULL
]	NULL
.	NULL

Gerrity	NULL
RG	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
monocyte	NULL
in	NULL
atherogenesis	NULL
,	NULL
I	NULL
:	NULL
transition	NULL
of	NULL
blood-borne	NULL
monocytes	NULL
into	NULL
foam	NULL
cells	NULL
in	NULL
fatty	NULL
lesions	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
.	NULL

1981	NULL
;	NULL
103:181-190	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7234961	NULL
]	NULL
.	NULL

Faggiotto	NULL
A	NULL
,	NULL
Ross	NULL
R	NULL
,	NULL
Harker	NULL
L.	NULL
Studies	NULL
of	NULL
hypercholesterolemia	NULL
in	NULL
the	NULL
nonhuman	NULL
primate	NULL
,	NULL
I	NULL
:	NULL
changes	NULL
that	NULL
lead	NULL
to	NULL
fatty	NULL
streak	NULL
formation	NULL
.	NULL

Arteriosclerosis	NULL
.	NULL

1984	NULL
;	NULL
4:323-340	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
6466191	NULL
]	NULL
.	NULL

Joris	NULL
I	NULL
,	NULL
Zand	NULL
T	NULL
,	NULL
Nunnari	NULL
JJ	NULL
,	NULL
Krolikowski	NULL
FJ	NULL
,	NULL
Majno	NULL
G.	NULL
Studies	NULL
on	NULL
the	NULL
pathogenesis	NULL
of	NULL
atherosclerosis	NULL
,	NULL
I	NULL
:	NULL
adhesion	NULL
and	NULL
emigration	NULL
of	NULL
mononuclear	NULL
cells	NULL
in	NULL
the	NULL
aorta	NULL
of	NULL
hypercholesterolemic	NULL
rats	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
.	NULL

1983	NULL
;	NULL
113:341-358	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
6650664	NULL
]	NULL
.	NULL

Li	NULL
H	NULL
,	NULL
Cybulsky	NULL
MI	NULL
,	NULL
Gimbrone	NULL
MA	NULL
Jr	NULL
,	NULL
Libby	NULL
P.	NULL
An	NULL
atherogenic	NULL
diet	NULL
rapidly	NULL
induces	NULL
VCAM-1	NULL
,	NULL
a	NULL
cytokine-regulatable	NULL
mononuclear	NULL
leukocyte	NULL
adhesion	NULL
molecule	NULL
,	NULL
in	NULL
rabbit	NULL
aortic	NULL
endothelium	NULL
.	NULL

Arterioscler	NULL
Thromb	NULL
.	NULL

1993	NULL
;	NULL
13:197-204	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7678986	NULL
]	NULL
.	NULL

Cybulsky	NULL
MI	NULL
,	NULL
Gimbrone	NULL
MA	NULL
Jr.	NULL
Endothelial	NULL
expression	NULL
of	NULL
a	NULL
mononuclear	NULL
leukocyte	NULL
adhesion	NULL
molecule	NULL
during	NULL
atherogenesis	NULL
.	NULL

Science	NULL
.	NULL

1991	NULL
;	NULL
251:788-791	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
1990440	NULL
]	NULL
.	NULL

Springer	NULL
TA	NULL
.	NULL

Traffic	NULL
signals	NULL
for	NULL
lymphocyte	NULL
recirculation	NULL
and	NULL
leukocyte	NULL
emigration	NULL
:	NULL
the	NULL
multistep	NULL
paradigm	NULL
.	NULL

Cell	NULL
.	NULL

1994	NULL
;	NULL
76:301-314	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7507411	NULL
]	NULL
.	NULL

O'Brien	NULL
KD	NULL
,	NULL
Allen	NULL
MD	NULL
,	NULL
McDonald	NULL
TO	NULL
,	NULL
Chait	NULL
A	NULL
,	NULL
Harlan	NULL
JM	NULL
,	NULL
Fishbein	NULL
D	NULL
,	NULL
McCarty	NULL
J	NULL
,	NULL
Ferguson	NULL
M	NULL
,	NULL
Hudkins	NULL
K	NULL
,	NULL
Benjamin	NULL
CD	NULL
,	NULL
Lobb	NULL
R	NULL
,	NULL
Alpers	NULL
CE	NULL
.	NULL

Vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
is	NULL
expressed	NULL
in	NULL
human	NULL
coronary	NULL
atherosclerotic	NULL
plaques	NULL
:	NULL
implications	NULL
for	NULL
the	NULL
mode	NULL
of	NULL
progression	NULL
of	NULL
advanced	NULL
coronary	NULL
atherosclerosis	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1993	NULL
;	NULL
92:945-951	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7688768	NULL
]	NULL
.	NULL

van	NULL
der	NULL
Wal	NULL
AC	NULL
,	NULL
Das	NULL
PK	NULL
,	NULL
Tigges	NULL
AJ	NULL
,	NULL
Becker	NULL
AE	NULL
.	NULL

Adhesion	NULL
molecules	NULL
on	NULL
the	NULL
endothelium	NULL
and	NULL
mononuclear	NULL
cells	NULL
in	NULL
human	NULL
atherosclerotic	NULL
lesions	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
.	NULL

1992	NULL
;	NULL
141:1427-1433	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
1281621	NULL
]	NULL
10	NULL
.	NULL

Pober	NULL
J	NULL
,	NULL
Cotran	NULL
RS	NULL
.	NULL

What	NULL
can	NULL
be	NULL
learned	NULL
from	NULL
the	NULL
expression	NULL
of	NULL
endothelial	NULL
adhesion	NULL
molecules	NULL
in	NULL
11.	NULL
tissues	NULL
?	NULL

Lab	NULL
Invest	NULL
.	NULL

1991	NULL
;	NULL
64:301-305	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
2002650	NULL
]	NULL
De	NULL
Caterina	NULL
R	NULL
,	NULL
Cybulsky	NULL
MI	NULL
,	NULL
Clinton	NULL
SK	NULL
,	NULL
Gimbrone	NULL
MA	NULL
Jr	NULL
,	NULL
Libby	NULL
P.	NULL
The	NULL
omega-3	NULL
fatty	NULL
acid	NULL
docosahexaencate	NULL
reduces	NULL
cytokine-induced	NULL
expression	NULL
of	NULL
proatherogenic	NULL
and	NULL
proinflammatory	NULL
proteins	NULL
in	NULL
human	NULL
endothelial	NULL
cells	NULL
.	NULL

Arterioscler	NULL
Thromb	NULL
.	NULL

1994	NULL
;	NULL
14:1829-1836	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7524649	NULL
]	NULL
12	NULL
.	NULL

Forman	NULL
BM	NULL
,	NULL
Chen	NULL
J	NULL
,	NULL
Evans	NULL
RM	NULL
.	NULL

Hypolipidemic	NULL
drugs	NULL
,	NULL
polyunsaturated	NULL
fatty	NULL
acids	NULL
,	NULL
and	NULL
13.	NULL
eicosanoids	NULL
are	NULL
ligands	NULL
for	NULL
peroxisome	NULL
proliferator-activated	NULL
receptors	NULL
alpha	NULL
and	NULL
delta	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1997	NULL
;	NULL
94:4312-4317	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9113986	NULL
]	NULL
Kliewer	NULL
SA	NULL
,	NULL
Sundseth	NULL
SS	NULL
,	NULL
Jones	NULL
SA	NULL
,	NULL
Brown	NULL
PJ	NULL
,	NULL
Wisely	NULL
GB	NULL
,	NULL
Koble	NULL
CS	NULL
,	NULL
Devehand	NULL
P	NULL
,	NULL
Wahli	NULL
W	NULL
,	NULL
Willson	NULL
TM	NULL
,	NULL
Lenhard	NULL
JM	NULL
,	NULL
Lehmann	NULL
JM	NULL
.	NULL

Fatty	NULL
acids	NULL
and	NULL
eicosanoids	NULL
regulate	NULL
gene	NULL
expression	NULL
through	NULL
direct	NULL
interactions	NULL
with	NULL
the	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
a	NULL
and	NULL
y.	NULL
Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
.	NULL

1997	NULL
;	NULL
94:4318-4323	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9113987	NULL
]	NULL
14	NULL
.	NULL

Staels	NULL
B	NULL
,	NULL
Dallongeville	NULL
J	NULL
,	NULL
Auwerx	NULL
J	NULL
,	NULL
Schoonjans	NULL
K	NULL
,	NULL
Leitersdorf	NULL
E	NULL
,	NULL
Fruchart	NULL
JC	NULL
.	NULL

Mechanism	NULL
of	NULL
15.	NULL
action	NULL
of	NULL
fibrates	NULL
on	NULL
lipid	NULL
and	NULL
lipoprotein	NULL
metabolism	NULL
.	NULL

Circulation	NULL
.	NULL

1998	NULL
;	NULL
98:2088-2093	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9808609	NULL
]	NULL
Schoonjans	NULL
K	NULL
,	NULL
Martin	NULL
G	NULL
,	NULL
Staels	NULL
B	NULL
,	NULL
Auwerx	NULL
J.	NULL
Peroxisome	NULL
proliferator-activated	NULL
receptors	NULL
,	NULL
orphans	NULL
with	NULL
ligands	NULL
and	NULL
functions	NULL
.	NULL

Curr	NULL
Opin	NULL
Lipidol	NULL
.	NULL

1997	NULL
;	NULL
8:159-166	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9211064	NULL
]	NULL
16	NULL
.	NULL

Marx	NULL
N	NULL
,	NULL
Bourcier	NULL
T	NULL
,	NULL
Sukhova	NULL
G	NULL
,	NULL
Libby	NULL
P	NULL
,	NULL
Plutzky	NULL
J.	NULL
PPARy	NULL
activation	NULL
in	NULL
human	NULL
endothelial	NULL
cells	NULL
increases	NULL
plasminogen	NULL
activator	NULL
inhibitor	NULL
type-1	NULL
expression	NULL
:	NULL
PPARy	NULL
as	NULL
a	NULL
potential	NULL
mediator	NULL
in	NULL
vascular	NULL
disease	NULL
.	NULL

Arterioscler	NULL
Thromb	NULL
Vase	NULL
Biol	NULL
.	NULL

1999	NULL
;	NULL
19:546-551	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10073956	NULL
]	NULL
17	NULL
.	NULL

Inoue	NULL
I	NULL
,	NULL
Shino	NULL
K	NULL
,	NULL
Noji	NULL
S	NULL
,	NULL
Awata	NULL
T	NULL
,	NULL
Katayama	NULL
S.	NULL
Expression	NULL
of	NULL
peroxisome	NULL
proliferator-activated	NULL
18.	NULL
receptor	NULL
alpha	NULL
(	NULL
PPAR	NULL
alpha	NULL
)	NULL
in	NULL
primary	NULL
cultures	NULL
of	NULL
human	NULL
vascular	NULL
endothelial	NULL
cells	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
.	NULL

1998	NULL
;	NULL
246:370-374	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9610365	NULL
]	NULL
Marx	NULL
N	NULL
,	NULL
Sukhova	NULL
G	NULL
,	NULL
Murphy	NULL
C	NULL
,	NULL
Libby	NULL
P	NULL
,	NULL
Plutzky	NULL
J.	NULL
Macrophages	NULL
in	NULL
human	NULL
atheroma	NULL
contain	NULL
PPARy	NULL
:	NULL
differentiation-dependent	NULL
PPARy	NULL
expression	NULL
and	NULL
reduction	NULL
of	NULL
MMP-9	NULL
activity	NULL
through	NULL
PPARy	NULL
activation	NULL
in	NULL
mononuclear	NULL
phagocytes	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
.	NULL

1998	NULL
;	NULL
153:17-23	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9665460	NULL
]	NULL
Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

Page	NULL
10	NULL
Luscinskas	NULL
FW	NULL
,	NULL
Cybulsky	NULL
MI	NULL
,	NULL
Kiely	NULL
JM	NULL
,	NULL
Peckins	NULL
CS	NULL
,	NULL
Davis	NULL
VM	NULL
,	NULL
Gimbrone	NULL
MA	NULL
Jr.	NULL
Cytokine-activated	NULL
human	NULL
endothelial	NULL
monolayers	NULL
support	NULL
enhanced	NULL
neutrophil	NULL
transmigration	NULL
via	NULL
a	NULL
mechanism	NULL
involving	NULL
both	NULL
endothelial-leukocyte	NULL
adhesion	NULL
molecule-1	NULL
and	NULL
intercellular	NULL
adhesion	NULL
molecule-1	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1991	NULL
;	NULL
146:1617-1625	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
1704400	NULL
]	NULL
Neish	NULL
AS	NULL
,	NULL
Williams	NULL
AJ	NULL
,	NULL
Palmer	NULL
HJ	NULL
,	NULL
Whitley	NULL
MZ	NULL
,	NULL
Collins	NULL
T.	NULL
Functional	NULL
analysis	NULL
of	NULL
the	NULL
human	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule	NULL
1	NULL
promoter	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1992	NULL
;	NULL
176:1583-1593	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
1281211	NULL
]	NULL
Chen	NULL
C	NULL
,	NULL
Okayama	NULL
H.	NULL
High-efficiency	NULL
transformation	NULL
of	NULL
mammalian	NULL
cells	NULL
by	NULL
plasmid	NULL
DNA	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1987	NULL
;	NULL
7:2745-2752	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
3670292	NULL
]	NULL
Neish	NULL
AS	NULL
,	NULL
Read	NULL
MA	NULL
,	NULL
Thanos	NULL
D	NULL
,	NULL
Pine	NULL
R	NULL
,	NULL
Maniatis	NULL
T	NULL
,	NULL
Collins	NULL
T.	NULL
Endothelial	NULL
interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
cooperates	NULL
with	NULL
NF-KB	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
of	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule	NULL
1	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1995	NULL
;	NULL
15:2558-2569	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7537851	NULL
]	NULL
Sterchele	NULL
PF	NULL
,	NULL
Sun	NULL
H	NULL
,	NULL
Peterson	NULL
RE	NULL
,	NULL
Vanden	NULL
Heuvel	NULL
JP	NULL
.	NULL

Regulation	NULL
of	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor-alpha	NULL
mRNA	NULL
in	NULL
rat	NULL
liver	NULL
.	NULL

Arch	NULL
Biochem	NULL
Biophys	NULL
.	NULL

1996	NULL
;	NULL
326:28	NULL
1-289	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8611035	NULL
]	NULL
Lee	NULL
SS	NULL
,	NULL
Pineau	NULL
T	NULL
,	NULL
Drago	NULL
J	NULL
,	NULL
Lee	NULL
EJ	NULL
,	NULL
Owens	NULL
JW	NULL
,	NULL
Kroetz	NULL
DL	NULL
,	NULL
Fernandez-Salguero	NULL
PM	NULL
,	NULL
Westphal	NULL
H	NULL
,	NULL
Gonzalez	NULL
FJ	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
the	NULL
alpha	NULL
isoform	NULL
of	NULL
the	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
gene	NULL
in	NULL
mice	NULL
results	NULL
in	NULL
abolishment	NULL
of	NULL
the	NULL
pleiotropic	NULL
effects	NULL
of	NULL
peroxisome	NULL
proliferators	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1995	NULL
;	NULL
15:3012-3022	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7539101	NULL
]	NULL
Staels	NULL
B	NULL
,	NULL
Koenig	NULL
W	NULL
,	NULL
Habib	NULL
A	NULL
,	NULL
Merval	NULL
R	NULL
,	NULL
Lebret	NULL
M	NULL
,	NULL
Pineda	NULL
Torra	NULL
I	NULL
,	NULL
Delerive	NULL
P	NULL
,	NULL
Fadel	NULL
A	NULL
,	NULL
Chinetti	NULL
G	NULL
,	NULL
Fruchart	NULL
J-C	NULL
,	NULL
Najib	NULL
J	NULL
,	NULL
Maclouf	NULL
J	NULL
,	NULL
Tedgui	NULL
A.	NULL
Activation	NULL
of	NULL
human	NULL
aortic	NULL
smooth	NULL
muscle	NULL
cells	NULL
is	NULL
inhibited	NULL
by	NULL
PPARa	NULL
but	NULL
not	NULL
by	NULL
PPARy	NULL
activators	NULL
.	NULL

Nature	NULL
.	NULL

1998	NULL
;	NULL
393:790-793	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9655393	NULL
]	NULL
Krey	NULL
G	NULL
,	NULL
Braissant	NULL
O	NULL
,	NULL
L	NULL
'	NULL
Horset	NULL
F	NULL
,	NULL
Kalkhoven	NULL
E	NULL
,	NULL
Perroud	NULL
M	NULL
,	NULL
Parker	NULL
MG	NULL
,	NULL
Wahli	NULL
W.	NULL
Fatty	NULL
acids	NULL
,	NULL
eicosanoids	NULL
,	NULL
and	NULL
hypolipidemic	NULL
agents	NULL
identified	NULL
as	NULL
ligands	NULL
of	NULL
peroxisome	NULL
proliferator-activated	NULL
receptors	NULL
by	NULL
coactivatordependent	NULL
receptor	NULL
ligand	NULL
assay	NULL
.	NULL

Mol	NULL
Endocrinol	NULL
.	NULL

1997	NULL
;	NULL
11:779-791	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9171241	NULL
]	NULL
Vu-Dac	NULL
N	NULL
,	NULL
Schoonjans	NULL
K	NULL
,	NULL
Kosykh	NULL
V	NULL
,	NULL
Dallongeville	NULL
J	NULL
,	NULL
Fruchart	NULL
JC	NULL
,	NULL
Staels	NULL
B	NULL
,	NULL
Auwerx	NULL
J.	NULL
Fibrates	NULL
increase	NULL
human	NULL
apolipoprotein	NULL
A-II	NULL
expression	NULL
through	NULL
activation	NULL
of	NULL
the	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1995	NULL
;	NULL
96:741-750	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7635967	NULL
]	NULL
Ray	NULL
P	NULL
,	NULL
Ghosh	NULL
SK	NULL
,	NULL
Zhang	NULL
DH	NULL
,	NULL
Ray	NULL
A.	NULL
Repression	NULL
of	NULL
interleukin-6	NULL
gene	NULL
expression	NULL
by	NULL
17b-estradiol	NULL
:	NULL
inhibition	NULL
of	NULL
the	NULL
DNA-binding	NULL
activity	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
NF-IL6	NULL
and	NULL
NF-xB	NULL
by	NULL
the	NULL
estrogen	NULL
receptor	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

1997	NULL
;	NULL
409:79-85	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9199508	NULL
]	NULL
Schule	NULL
R	NULL
,	NULL
Rangarajan	NULL
P	NULL
,	NULL
Yang	NULL
N	NULL
,	NULL
Kliewer	NULL
S	NULL
,	NULL
Ransone	NULL
LJ	NULL
,	NULL
Bolado	NULL
J	NULL
,	NULL
Verma	NULL
IM	NULL
,	NULL
Evans	NULL
RM	NULL
.	NULL

Retinoic	NULL
acid	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
AP-1-responsive	NULL
genes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1991	NULL
;	NULL
88:6092-6096	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
1648728	NULL
]	NULL
Gerritsen	NULL
ME	NULL
,	NULL
Williams	NULL
AJ	NULL
,	NULL
Neish	NULL
AS	NULL
,	NULL
Moore	NULL
S	NULL
,	NULL
Shi	NULL
Y	NULL
,	NULL
Collins	NULL
T.	NULL
CREB-binding	NULL
protein/p300	NULL
are	NULL
transcriptional	NULL
co-activators	NULL
of	NULL
p65	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Science	NULL
.	NULL

1997	NULL
;	NULL
94:2927-2932	NULL
.	NULL

Dowell	NULL
P	NULL
,	NULL
Ishmael	NULL
JE	NULL
,	NULL
Avram	NULL
D	NULL
,	NULL
Peterson	NULL
VJ	NULL
,	NULL
Nevrivy	NULL
DJ	NULL
,	NULL
Leid	NULL
M.	NULL
p300	NULL
functions	NULL
as	NULL
a	NULL
coactivator	NULL
for	NULL
the	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
alpha	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

1997	NULL
;	NULL
272:33435-33443	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9407140	NULL
]	NULL
Collins	NULL
T	NULL
,	NULL
Read	NULL
MA	NULL
,	NULL
Neish	NULL
AS	NULL
,	NULL
Whitley	NULL
MZ	NULL
,	NULL
Thanos	NULL
D	NULL
,	NULL
Maniatis	NULL
T.	NULL
Transcriptional	NULL
regulation	NULL
of	NULL
endothelial	NULL
cell	NULL
adhesion	NULL
molecules	NULL
:	NULL
NF-kappa	NULL
B	NULL
and	NULL
cytokine-inducible	NULL
enhancers	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

1995	NULL
;	NULL
9:899-909	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7542214	NULL
]	NULL
Gille	NULL
J	NULL
,	NULL
Paxton	NULL
LL	NULL
,	NULL
Lawley	NULL
TJ	NULL
,	NULL
Caughman	NULL
SW	NULL
,	NULL
Swerlick	NULL
RA	NULL
.	NULL

Retinoic	NULL
acid	NULL
inhibits	NULL
the	NULL
regulated	NULL
expression	NULL
of	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
by	NULL
cultured	NULL
dermal	NULL
microvascular	NULL
endothelial	NULL
cells	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1997	NULL
;	NULL
99:492-500	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9022083	NULL
]	NULL
Weil	NULL
A	NULL
,	NULL
Caldwell	NULL
J	NULL
,	NULL
Strolin-Benedetti	NULL
M.	NULL
The	NULL
metabolism	NULL
and	NULL
disposition	NULL
of	NULL
14C-fenofibrate	NULL
in	NULL
human	NULL
volunteers	NULL
.	NULL

Drug	NULL
Metab	NULL
Dispos	NULL
.	NULL

1990	NULL
;	NULL
18:1	NULL
15-120	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
1970770	NULL
]	NULL
Hahmann	NULL
HW	NULL
,	NULL
Bunte	NULL
T	NULL
,	NULL
Hellwig	NULL
N	NULL
,	NULL
Hau	NULL
U	NULL
,	NULL
Becker	NULL
D	NULL
,	NULL
Dyckmans	NULL
J	NULL
,	NULL
Keller	NULL
HE	NULL
,	NULL
Schieffer	NULL
HJ	NULL
.	NULL

Progression	NULL
and	NULL
regression	NULL
of	NULL
minor	NULL
coronary	NULL
arterial	NULL
narrowings	NULL
by	NULL
quantitative	NULL
angiography	NULL
after	NULL
fenofibrate	NULL
therapy	NULL
.	NULL

Am	NULL
J	NULL
Cardiol	NULL
.	NULL

1991	NULL
;	NULL
67:957-961	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
2018014	NULL
]	NULL
Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
11	NULL
36	NULL
.	NULL

Kromhout	NULL
D	NULL
,	NULL
Bosschieter	NULL
EB	NULL
,	NULL
de	NULL
Lezenne	NULL
Coulander	NULL
C.	NULL
The	NULL
inverse	NULL
relation	NULL
between	NULL
fish	NULL
consumption	NULL
and	NULL
20-year	NULL
mortality	NULL
from	NULL
coronary	NULL
heart	NULL
disease	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
.	NULL

1985	NULL
;	NULL
312:1205-1209	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
3990713	NULL
]	NULL
37	NULL
.	NULL

Davis	NULL
HR	NULL
,	NULL
Bridenstine	NULL
RT	NULL
,	NULL
Vesselinovitch	NULL
D	NULL
,	NULL
Wissler	NULL
RW	NULL
.	NULL

Fish	NULL
oil	NULL
inhibits	NULL
development	NULL
of	NULL
atherosclerosis	NULL
in	NULL
rhesus	NULL
monkeys	NULL
.	NULL

Arteriosclerosis	NULL
.	NULL

1987	NULL
;	NULL
7:441-449	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
3675303	NULL
]	NULL
38	NULL
.	NULL

Harker	NULL
LA	NULL
,	NULL
Kelly	NULL
AB	NULL
,	NULL
Hanson	NULL
SR	NULL
,	NULL
Krupski	NULL
W	NULL
,	NULL
Bass	NULL
A	NULL
,	NULL
Osterud	NULL
B	NULL
,	NULL
FitzGerald	NULL
GA	NULL
,	NULL
Goodnight	NULL
SH	NULL
,	NULL
Connor	NULL
WE	NULL
.	NULL

Interruption	NULL
of	NULL
vascular	NULL
thrombus	NULL
formation	NULL
and	NULL
vascular	NULL
lesion	NULL
formation	NULL
by	NULL
dietary	NULL
n-3	NULL
fatty	NULL
acids	NULL
in	NULL
fish	NULL
oil	NULL
in	NULL
nonhuman	NULL
primates	NULL
.	NULL

Circulation	NULL
.	NULL

1993	NULL
;	NULL
87:1017-1029	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8443878	NULL
]	NULL
Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
12	NULL
«	NULL
s	NULL
62	NULL
kD	NULL
PPARQ	NULL
im	NULL
«	NULL
s	NULL
47.5	NULL
kD	NULL
(	NULL
52	NULL
kD	NULL
)	NULL
Co	NULL
-	NULL
Nucl	NULL
Cyto	NULL
Figure	NULL
1	NULL
.	NULL

ECs	NULL
express	NULL
PPARa	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
.	NULL

A	NULL
,	NULL
PPARa	NULL
expression	NULL
in	NULL
nuclei	NULL
of	NULL
ECs	NULL
of	NULL
human	NULL
carotid	NULL
arteries	NULL
(	NULL
positive	NULL
nuclei	NULL
stained	NULL
blue	NULL
,	NULL
arrowheads	NULL
)	NULL
.	NULL

B	NULL
,	NULL
Parallel	NULL
sections	NULL
stained	NULL
with	NULL
goat	NULL
IgG	NULL
show	NULL
no	NULL
signal	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
staining	NULL
for	NULL
PPARa	NULL
is	NULL
specific	NULL
.	NULL

C	NULL
,	NULL
Immunostaining	NULL
of	NULL
parallel	NULL
sections	NULL
with	NULL
CD31	NULL
identifies	NULL
endothelial	NULL
cell	NULL
layer	NULL
at	NULL
luminal	NULL
surface	NULL
of	NULL
artery	NULL
(	NULL
stained	NULL
red	NULL
)	NULL
.	NULL

Magnification	NULL
x400	NULL
in	NULL
all	NULL
.	NULL

Analysis	NULL
of	NULL
6	NULL
separate	NULL
carotid	NULL
sections	NULL
revealed	NULL
similar	NULL
results	NULL
.	NULL

D	NULL
,	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
cultured	NULL
human	NULL
saphenous	NULL
vein	NULL
ECs	NULL
reveals	NULL
PPARa	NULL
protein	NULL
expression	NULL
in	NULL
nuclear	NULL
extracts	NULL
(	NULL
Nucl	NULL
)	NULL
.	NULL

Identity	NULL
of	NULL
detected	NULL
band	NULL
Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
13	NULL
was	NULL
confirmed	NULL
by	NULL
comigration	NULL
with	NULL
a	NULL
band	NULL
from	NULL
fibroblasts	NULL
transfected	NULL
with	NULL
a	NULL
PPARa	NULL
expression	NULL
construct	NULL
(	NULL
Co	NULL
)	NULL
.	NULL

PPARa	NULL
is	NULL
not	NULL
seen	NULL
in	NULL
cytosolic	NULL
fraction	NULL
of	NULL
ECs	NULL
(	NULL
Cyto	NULL
)	NULL
.	NULL

Three	NULL
independent	NULL
experiments	NULL
showed	NULL
similar	NULL
results	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

>	NULL
100	NULL
___	NULL
80	NULL
s	NULL
$	NULL
60	NULL
<	NULL
8	NULL
°	NULL
40	NULL
-	NULL
»	NULL
&	NULL
20	NULL
0	NULL
TNF-100	NULL
_	NULL
,	NULL
80	NULL
I	NULL
o	NULL
8	NULL
40	NULL
-	NULL
»	NULL
€	NULL
20	NULL
0	NULL
time	NULL
of	NULL
pretreatment	NULL
Page	NULL
14	NULL
B	NULL
[	NULL
]	NULL
E-Selectin	NULL
100	NULL
_	NULL
80	NULL
2	NULL
**	NULL
C	NULL
60	NULL
|	NULL
xx	NULL
0	NULL
**	NULL
0	NULL
40	NULL
3°	NULL
tcc	NULL
**	NULL
20	NULL
I	NULL
0	NULL
-	NULL
+	NULL
+o	NULL
oo+	NULL
+	NULL
+	NULL
+	NULL
TNF-	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
None	NULL
feno	NULL
WY	NULL
trogl	NULL
PGJ2	NULL
BRL	NULL
None	NULL
feno	NULL
WY	NULL
trogl	NULL
PGJZ2	NULL
BRL	NULL
D	NULL
'	NULL
H	NULL
TNF-	NULL
«	NULL
C	NULL
100	NULL
_	NULL
4	NULL
-	NULL
80	NULL
*	NULL
s	NULL
E	NULL
60	NULL
x*	NULL
68	NULL
40	NULL
-	NULL
>	NULL
&	NULL
20	NULL
I	NULL
U	NULL
I	NULL
U	NULL
I	NULL
0	NULL
1	NULL
h	NULL
6	NULL
h	NULL
12	NULL
h	NULL
18	NULL
h	NULL
24	NULL
h	NULL
Cytokines	NULL
~	NULL
+	NULL
+	NULL
+	NULL
+	NULL
100	NULL
uM	NULL
fenofibrate	NULL
uM	NULL
fenofibrate	NULL
Figure	NULL
2	NULL
.	NULL

PPARa	NULL
but	NULL
not	NULL
PPARy	NULL
activators	NULL
inhibit	NULL
cytokine-induced	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
VCAM-1	NULL
in	NULL
human	NULL
ECs	NULL
.	NULL

A	NULL
and	NULL
B	NULL
,	NULL
Cells	NULL
were	NULL
pretreated	NULL
with	NULL
PPARa	NULL
[	NULL
100	NULL
umol/L	NULL
fenofibrate	NULL
(	NULL
feno	NULL
)	NULL
,	NULL
250	NULL
umol/L	NULL
WY14643	NULL
(	NULL
WY	NULL
)	NULL
]	NULL
or	NULL
PPARy	NULL
[	NULL
10	NULL
umol/L	NULL
troglitazone	NULL
(	NULL
trogl	NULL
)	NULL
,	NULL
10	NULL
umol/L	NULL
15d-PGJ2	NULL
(	NULL
PGJ2	NULL
)	NULL
,	NULL
10	NULL
umol/L	NULL
BRLA9653	NULL
(	NULL
BRL	NULL
)	NULL
]	NULL
activators	NULL
for	NULL
24	NULL
hours	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
TNF-a	NULL
10	NULL
ug/L	NULL
for	NULL
8	NULL
hours	NULL
before	NULL
cell	NULL
surface	NULL
EIAs	NULL
were	NULL
performed	NULL
for	NULL
VCAM-1	NULL
(	NULL
A	NULL
)	NULL
,	NULL
ICAM-1	NULL
,	NULL
and	NULL
E-selectin	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
percent	NULL
of	NULL
TNF-a-stimulated	NULL
cells	NULL
(	NULL
%	NULL
control	NULL
)	NULL
.	NULL

Bars	NULL
represent	NULL
mean+8SEM	NULL
(	NULL
VCAM-1	NULL
,	NULL
n=8	NULL
;	NULL
ICAM-1/E-selectin	NULL
,	NULL
n=4	NULL
)	NULL
;	NULL
*P	NULL
<	NULL
0.05	NULL
,	NULL
**P	NULL
<	NULL
0.01	NULL
vs	NULL
control	NULL
.	NULL

C	NULL
and	NULL
D	NULL
,	NULL
PPARa	NULL
activators	NULL
inhibit	NULL
surface	NULL
expression	NULL
of	NULL
VCAM-1	NULL
in	NULL
human	NULL
ECs	NULL
in	NULL
a	NULL
time-	NULL
and	NULL
concentration-dependent	NULL
manner	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
with	NULL
fenofibrate	NULL
100	NULL
umol/L	NULL
for	NULL
duration	NULL
shown	NULL
before	NULL
stimulation	NULL
with	NULL
TNF-a	NULL
10	NULL
ug/L	NULL
for	NULL
8	NULL
hours	NULL
(	NULL
C	NULL
)	NULL
.	NULL

ECs	NULL
were	NULL
pretreated	NULL
with	NULL
fenofibrate	NULL
at	NULL
concentrations	NULL
shown	NULL
for	NULL
24	NULL
hours	NULL
,	NULL
before	NULL
stimulation	NULL
with	NULL
TNF-a	NULL
10	NULL
ug/L	NULL
(	NULL
D	NULL
,	NULL
solid	NULL
bars	NULL
)	NULL
,	NULL
or	NULL
IL-1a	NULL
10	NULL
ug/L	NULL
(	NULL
D	NULL
,	NULL
open	NULL
bars	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
percent	NULL
of	NULL
cytokine-stimulated	NULL
cells	NULL
(	NULL
%	NULL
control	NULL
)	NULL
as	NULL
determined	NULL
by	NULL
cell	NULL
surface	NULL
EIA	NULL
.	NULL

Circles/bars	NULL
represent	NULL
mean+SEM	NULL
(	NULL
n=3	NULL
)	NULL
;	NULL
*P	NULL
<	NULL
0.05	NULL
,	NULL
**P	NULL
<	NULL
0.01	NULL
vs	NULL
control	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
15	NULL
TNF-o	NULL
TNF-a	NULL
+	NULL
fenofibrate	NULL
Co	NULL
O	NULL
]	NULL
O	NULL
)	NULL
C	NULL
1	NULL
**	NULL
**	NULL
NJ	NULL
C	NULL
N	NULL
(	NULL
x	NULL
10°	NULL
cells	NULL
/	NULL
cm	NULL
?	NULL
)	NULL

-	NULL
[	NULL
Cd	NULL
|	NULL
*	NULL
*	NULL
e	NULL
__	NULL
TNF-	NULL
-	NULL
+	NULL
+	NULL
+	NULL
None	NULL
feno	NULL
WY	NULL
Leukocyte	NULL
adherence	NULL
Figure	NULL
3	NULL
.	NULL

PPARa	NULL
activators	NULL
inhibit	NULL
adhesion	NULL
of	NULL
U937	NULL
monocytoid	NULL
cells	NULL
to	NULL
human	NULL
ECs	NULL
.	NULL

A	NULL
,	NULL
Fluorescein-labeled	NULL
U937	NULL
cells	NULL
were	NULL
added	NULL
to	NULL
TNF-a	NULL
10	NULL
ug/L-stimulated	NULL
human	NULL
EC	NULL
monolayers	NULL
with	NULL
or	NULL
without	NULL
fenofibrate	NULL
pretreatment	NULL
.	NULL

Fluorescence	NULL
microscopy	NULL
shows	NULL
adherent	NULL
U937	NULL
cells	NULL
(	NULL
green	NULL
)	NULL
on	NULL
ECs	NULL
.	NULL

B	NULL
,	NULL
Quantification	NULL
of	NULL
U937	NULL
adherence	NULL
on	NULL
EC	NULL
monolayers	NULL
after	NULL
EC	NULL
pretreatment	NULL
with	NULL
fenofibrate	NULL
(	NULL
feno	NULL
)	NULL
100	NULL
umol/L	NULL
or	NULL
WY14643	NULL
(	NULL
WY	NULL
)	NULL
250	NULL
umol/L	NULL
as	NULL
determined	NULL
by	NULL
fluorescence	NULL
assay	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
cells/cm	NULL
.	NULL

Bars	NULL
represent	NULL
mean+SEM	NULL
(	NULL
n=3	NULL
)	NULL
;	NULL
**P	NULL
<	NULL
0.01	NULL
vs	NULL
TNF-a	NULL
stimulated	NULL
cells	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
16	NULL
VCAM	NULL
#	NULL
...	NULL
#	NULL
B	NULL
wwe	NULL
=	NULL
>	NULL
285	NULL
#	NULL
m	NULL
185	NULL
-m	NULL
TNF-	NULL
_	NULL
>	NULL
-	NULL
+	NULL
$	NULL
00	NULL
o	NULL
$	NULL
+	NULL
=	NULL
+	NULL
$	NULL
o	NULL
4	NULL
+	NULL
O	NULL
1	NULL
10	NULL
100	NULL
0	NULL
-	NULL
2.5	NULL
25	NULL
250	NULL
uM	NULL
fenofibrate	NULL
uM	NULL
WY14643	NULL
i	NULL
a	NULL
r	NULL
=	NULL
--	NULL
-	NULL
TNEF-C	NULL
&	NULL
0.754	NULL
e	NULL
>	NULL
-	NULL
TNF-0	NULL
+	NULL
fenofibrate	NULL
S	NULL
C	NULL
(	NULL
0.54	NULL
es	NULL
bd	NULL
F	NULL
I	NULL
0.254	NULL
®	NULL
Q	NULL
ooo	NULL
0	NULL
P	NULL
4	NULL
6	NULL
8	NULL
10	NULL
12	NULL
14	NULL
time	NULL
(	NULL
h	NULL
)	NULL
Figure	NULL
4	NULL
.	NULL

PPARa	NULL
activators	NULL
inhibit	NULL
VCAM-1	NULL
mRNA	NULL
expression	NULL
but	NULL
not	NULL
mRNA	NULL
half-life	NULL
in	NULL
human	NULL
ECs	NULL
.	NULL

A	NULL
,	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
ECs	NULL
pretreated	NULL
with	NULL
fenofibrate	NULL
or	NULL
W	NULL
Y14643	NULL
at	NULL
concentrations	NULL
shown	NULL
for	NULL
24	NULL
hours	NULL
before	NULL
stimulation	NULL
with	NULL
TNF-a	NULL
10	NULL
ug/L	NULL
for	NULL
3	NULL
hours	NULL
(	NULL
top	NULL
)	NULL
.	NULL

Ethidium	NULL
bromide	NULL
staining	NULL
(	NULL
bottom	NULL
)	NULL
demonstrates	NULL
equal	NULL
loading	NULL
of	NULL
intact	NULL
RNA	NULL
.	NULL

Three	NULL
independent	NULL
experiments	NULL
yielded	NULL
similar	NULL
results	NULL
.	NULL

B	NULL
,	NULL
Densitometry	NULL
analysis	NULL
of	NULL
TNF-a-induced	NULL
VCAM-1	NULL
mRNA	NULL
levels	NULL
in	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
fenofibrate	NULL
100	NULL
umol/L	NULL
as	NULL
measured	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
actinomycin	NULL
D-treated	NULL
ECs	NULL
.	NULL

Actinomycin	NULL
D	NULL
and	NULL
Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
17	NULL
fenofibrate	NULL
were	NULL
added	NULL
to	NULL
ECs	NULL
3	NULL
hours	NULL
after	NULL
TNF-a	NULL
stimulation	NULL
(	NULL
0	NULL
hours	NULL
)	NULL
;	NULL
cells	NULL
were	NULL
harvested	NULL
at	NULL
times	NULL
indicated	NULL
.	NULL

Amount	NULL
of	NULL
mRNA	NULL
at	NULL
each	NULL
time	NULL
point	NULL
was	NULL
compared	NULL
with	NULL
mRNA	NULL
levels	NULL
after	NULL
3	NULL
hours	NULL
of	NULL
TNF-a	NULL
stimulation	NULL
at	NULL
time	NULL
0	NULL
hours	NULL
(	NULL
ordinate	NULL
labeled	NULL
as	NULL
relative	NULL
mRNA	NULL
level	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
shown	NULL
as	NULL
mean6SEM	NULL
of	NULL
3	NULL
independent	NULL
experiments	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
18	NULL
AP-1	NULL
GATA	NULL
NF-rE	NULL
TATAA	NULL
NF-	NULL
«	NULL
B	NULL
TATAA	NULL
F4	NULL
(	NULL
-44	NULL
)	NULL
TATAA	NULL
Co	NULL
TNF-C	NULL
TNF-	NULL
@	NULL
+	NULL
fenofibrate	NULL
E=	NULL
1	NULL
fenofibrate	NULL
a	NULL
FQ	NULL
F3	NULL
8B	NULL
=-	NULL
s	NULL
©	NULL
O0	NULL
®	NULL
CJ	NULL
fold	NULL
induction	NULL
(	NULL
CAT	NULL
/	NULL
ft-GAL	NULL
)	NULL
Jz	NULL
1	NULL
F4	NULL
C.	NULL
TNF-C	NULL
=o	NULL
pop	NULL
<	NULL
40	NULL
4	NULL
4	NULL
o	NULL
$	NULL
$	NULL
4	NULL
+4	NULL
fenofibrate	NULL
-	NULL
-	NULL
+	NULL
+	NULL
-~	NULL
-	NULL
#	NULL
4	NULL
-~	NULL
4	NULL
-	NULL
+	NULL
#	NULL
anti-p50	NULL
-o-	NULL
«	NULL
w	NULL
w	NULL
w	NULL
0	NULL
pou	NULL
ok	NULL
&	NULL
ok	NULL
&	NULL
anti-p65	NULL
we	NULL
,	NULL
eo	NULL
mics	NULL
eae	NULL
om	NULL
cn	NULL
onl	NULL
cme	NULL
ow	NULL
IgG	NULL
hsm	NULL
nop	NULL
cumideck	NULL
-f	NULL
a	NULL
a	NULL
+	NULL
cold	NULL
probe	NULL
«	NULL
@	NULL
Supershift	NULL
-	NULL
#	NULL
NF-xB	NULL
-a	NULL
A	NULL
Figure	NULL
5	NULL
.	NULL

Fenofibrate	NULL
inhibits	NULL
TNF-a-induced	NULL
activation	NULL
of	NULL
human	NULL
VCAM-1	NULL
promoter	NULL
and	NULL
activation	NULL
of	NULL
NF-xB	NULL
.	NULL

A	NULL
,	NULL
Deletional	NULL
series	NULL
of	NULL
VCAM-1	NULL
promoter	NULL
constructs	NULL
used	NULL
in	NULL
transfection	NULL
experiments	NULL
.	NULL

B	NULL
,	NULL
Bovine	NULL
ECs	NULL
were	NULL
cotransfected	NULL
with	NULL
VCAM-1	NULL
promoter	NULL
deletion	NULL
constructs	NULL
indicated	NULL
and	NULL
a	NULL
B-galactosidase	NULL
expression	NULL
construct	NULL
(	NULL
pCMV.B-GAL	NULL
)	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
agents	NULL
indicated	NULL
for	NULL
36	NULL
hours	NULL
,	NULL
and	NULL
assays	NULL
were	NULL
performed	NULL
for	NULL
CAT-	NULL
and	NULL
B-galactosidase	NULL
activity	NULL
.	NULL

Results	NULL
for	NULL
each	NULL
construct	NULL
were	NULL
normalized	NULL
to	NULL
b-galactosidase	NULL
activity	NULL
and	NULL
expressed	NULL
as	NULL
multiples	NULL
of	NULL
induction	NULL
compared	NULL
with	NULL
unstimulated	NULL
cells	NULL
.	NULL

Bars	NULL
represent	NULL
Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14.	NULL
iduosnuep	NULL
1ouiny	NULL
yd-HIN	NULL
iduosnuep	NULL
10uiny	NULL
Vd-HIN	NULL
iduosnuep	NULL
1ouiny	NULL
Yd-HIN	NULL
Marx	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
19	NULL
mean+SEM	NULL
(	NULL
n=3	NULL
)	NULL
;	NULL
*P	NULL
<	NULL
0.05	NULL
vs	NULL
TNF-a-	NULL
stimulated	NULL
cells	NULL
.	NULL

C	NULL
,	NULL
EMSA	NULL
of	NULL
human	NULL
ECs	NULL
pretreated	NULL
with	NULL
fenofibrate	NULL
100	NULL
umol/L	NULL
for	NULL
24	NULL
hours	NULL
before	NULL
TNF-a	NULL
stimulation	NULL
for	NULL
2	NULL
hours	NULL
.	NULL

Specificity	NULL
was	NULL
determined	NULL
by	NULL
addition	NULL
of	NULL
40	NULL
ng	NULL
unlabeled	NULL
NF-xB	NULL
oligonucleotide	NULL
(	NULL
cold	NULL
probe	NULL
)	NULL
.	NULL

Supershift	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
anti-p50	NULL
and	NULL
anti-p65	NULL
antibodies	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
nonspecific	NULL
IgG	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
seen	NULL
in	NULL
3	NULL
independent	NULL
experiments	NULL
.	NULL

Circulation	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2014	NULL
November	NULL
14	NULL
.	NULL

